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Adenosine is a purinergic signaling molecule that regulates various 
aspects of inflammation and has been implicated in the pathogenesis of chronic 
lung diseases.  Previous studies have demonstrated that adenosine up-regulates 
IL-6 production through the engagement of the A2B adenosine receptor in various 
cell types, including alveolar macrophages.  IL-6 is elevated in mouse models 
and humans with chronic lung disease, suggesting a potential role in disease 
progression.  Furthermore, chronic elevation of adenosine in the lungs of 
adenosine deaminase deficient (Ada-/-) mice leads to the development of 
pulmonary inflammation, alveolar destruction, and fibrosis, in conjunction with IL-
6 elevation.  Thus, it was hypothesized that IL-6 contributes to pulmonary 
inflammation and fibrosis in this model. To test this hypothesis, Ada/IL-6 double 
knockout mice (Ada/IL-6-/-) were generated to assess the consequences of 
genetically removing IL-6 on adenosine-dependent pulmonary injury.  Ada/IL-6-/- 
mice exhibited a significant reduction in inflammation, alveolar destruction, and 
pulmonary fibrosis.  Next, Ada-/- mice were treated systematically with IL-6 
neutralizing antibodies to test the efficacy of blocking IL-6 on chronic lung 
disease.  These treatments were associated with decreased pulmonary 
inflammation, alveolar destruction, and fibrosis.  To determine the role of IL-6 in a 
second model of pulmonary fibrosis, wild type mice and IL-6-/- mice were 
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subjected to intraperitoneal injections of bleomycin twice a week for four weeks.  
Results demonstrated that IL-6-/- mice developed reduced pulmonary fibrosis.  To 
examine a therapeutic approach in this model, wild type mice exposed to 
bleomycin were treated with IL-6 neutralizing antibodies.  Similar results were 
observed as with Ada-/- mice, namely diminished pulmonary inflammation and 
fibrosis.  In both models, elevations in IL-6 were associated with increased 
phosphorylated STAT-3 in the nuclei of numerous cell types in the airways, 
including type II alveolar epithelial cells (AEC).  Genetic removal and 
neutralization of IL-6 in both models was associated with decreased STAT-3 
activation in type II AEC.  The mechanism of activation in these cells that lack the 
membrane bound IL-6Rα suggests IL-6 trans-signaling may play a role in 
regulating fibrosis.  Characterization of this mechanism demonstrated that the 
soluble IL-6Rα (sIL-6Rα) is upregulated in both models during chronic conditions.  
In vitro studies in MLE-12 alveolar epithelial cells confirmed that IL-6, in 
combination with the sIL-6Rα, activates STAT-3 and TWIST in association with 
enhancement of epithelial-to-mesenchymal transition, which can contribute to 
fibrosis.  Similarly, patients with idiopathic pulmonary fibrosis demonstrated a 
similar pattern of increased IL-6 expression, STAT-3 activation, and sIL-6Rα 
increases.  These findings demonstrate that adenosine-dependent elevations in 
IL-6 contribute to the development and progression of pulmonary inflammation 
and fibrosis.  The implications from these studies are that adenosine and/or IL-6 
neutralizing agents represent novel therapeutic targets for the treatment of 
pulmonary disorders where fibrosis is a detrimental component. 
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CHRONIC LUNG DISEASES 
 Chronic lung disease is a general term describing pulmonary disorders 
where progressive decline in lung function is caused by persistent structural  
damage (1-3).  Chronic lung diseases are expensive, devastating and deadly, 
representing the third leading cause of death in America following cancer and 
cardiovascular diseases (4). The most prominent examples of chronic lung 
diseases are asthma, chronic obstructive pulmonary disease (COPD), and 
interstitial lung disease (ILD).  Asthma is characterized  by infiltration of 
lymphocytes and eosinophils together with airway remodeling, mucus 
hypersecretion, basement membrane thickening, angiogenesis, and collagen 
deposition around the bronchial airways (5).  In contrast, COPD is characterized 
by persistent bronchitis and emphysema due to monocytic inflammation and 
destruction of alveolar spaces caused by imbalances of proteases and anti-
proteases that regulate matrix metabolism (6).  ILDs, such as idiopathic 
pulmonary fibrosis (IPF), exhibit varying degrees in inflammation and fibrosis with 
the prominent features of excessive fibroblast proliferation and extensive matrix 
deposition in the alveolar spaces (7).  Accordingly, these diseases are 
characterized by a high morbidity and mortality rate (4). 
 The aforementioned chronic lung diseases are associated with various 
aspects of lung inflammation, tissue damage and remodeling (8).  Despite the 
diverse responses seen in these disorders, a common feature is the recruitment 
and activation of multiple effector cells that in turn release various mediators that 
promote additional inflammation and/or tissue remodeling (1, 8).  Although 
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substantial information is available concerning the biogenesis of the inflammatory 
and pathological features of chronic lung diseases, the mechanisms that promote 
the amplification and chronic nature of these disorders have not been adequately 
investigated (9).   
 This dissertation will focus on examining mechanisms by which the 
signaling molecule, adenosine, contributes to the amplification of chronic lung 
diseases.  The significance of this work lies in the fact that chronic lung diseases 
are largely untreatable.  Available therapies target the symptomatic features of 
these disorders, but fail to manage the extensive airway remodeling seen in 
these patients (10-12).  Thus, identifying signaling pathways responsible for the 
regulation of progressive pulmonary inflammation and persistent lung damage 
may provide novel therapeutic approaches for these devastating disorders. 
 
PULMONARY FIBROSIS 
 Interstitial lung disease (ILD) is a term used to describe a number of 
heterogeneous lung disorders sharing common features of variable degrees of 
pulmonary inflammation and extracellular matrix (ECM) remodeling in the 
parenchyma and alveolar space (7, 13).  Pulmonary fibrosis is the hallmark of 
ILDs and represents the end stage of these lung disorders.  There are known 
etiologies for certain ILDs.  Known causes of pulmonary fibrosis include 
environmental exposure to silica (14), asbestos (15), and coal dust , lifestyle 
factors such as tobacco use (16), chemotherapeutic drug-induced fibrosis (17), 
and genetic disorders such as scleroderma (18), sarcoidosis (19), and cystic 
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fibrosis (20).  However, many ILDs are idiopathic in nature.  Idiopathic pulmonary 
fibrosis (IPF) is the most common of these disorders and is associated with an 
appalling prognosis, much worse than that of many cancers.  IPF is generally 
lethal within three to five years from the time of diagnosis (13, 21).  The incidence 
of IPF is estimated to affect 500,000 individuals in the U.S. and Europe, with a 
40% mortality rate (22), affecting usually middle-aged and older adults with a 
prevalence 20% higher in males than females (23).  The lack of understanding of 
the pathogenesis of this condition is reflected in the need for effective therapies 
and our inability to modify the course of the disease.   
 Pulmonary fibrosis is commonly characterized by uncontrolled fibroblast 
proliferation, activation, and differentiation into contractile myofibroblasts, leading 
to ECM deposition that compromises lung function by distorting the pulmonary 
architecture (3, 7, 13).  The initiation and progression of fibrosis is thought to 
arise from a dysregulated epithelial-mesenchymal interaction promoting 
continued epithelial cell injury and leading to an aberrant wound repair 
mechanism.  Upon cellular injury, alveolar epithelial cells undergo apoptosis 
while secreting mediators that initiate the wound repair process (24).  
Inflammatory cells migrate to the site of injury and fibroblasts proliferate from the 
interstitium to the airways in order to form a provisional matrix (25).  Following 
resolution of the source of injury, the provisional matrix is degraded and new 
epithelialization occurs (26, 27).  However, if the source of injury persists, or if 
amplification pathways are engaged, the wound repair mechanism is deregulated 
and pulmonary fibrosis follows.   
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 In addition, infiltrating fibroblasts are transformed into myofibroblasts and 
collagen synthesis ensues in response to biological mediators.  Accumulation, 
proliferation, and activation of fibroblasts and myofibroblast differentiation 
represent the active site of injury, which is termed the ‘fibroblast foci’.  The 
myofibroblast is considered to be the primary effector cell of pulmonary fibrosis.  
Nevertheless, the origin of the myofibroblast is not clearly established.  Three 
potential sources have been hypothesized for the observed myofibroblast 
accumulation and differentiation.  These are: i) Proliferation and conversion of 
resident lung fibroblasts into myofibroblasts (28); ii) Bone-marrow derived 
circulating fibrocytes, which serve as progenitors for interstitial fibroblast with the 
potential to differentiate into myofibroblasts (29); and iii) The contribution from a 
process known as epithelial-mesenchymal transition (EMT), which is the 
differentiation from a epithelial cell to a mesenchymal, fibroblast-like phenotype 
resulting in myofibroblast accumulation (30).  There are studies indicating that 
“endothelial-mesenchymal transition” also occurs in lung capillary endothelial 
cells (31).  The different sources of myofibroblasts support the notion that fibrosis 
occurs as the result of abnormal wound healing responses and persistent 
epithelial injury independent of inflammation. 
 The histopathology of IPF is best represented by a heterogeneous patchy 
distribution of fibrosis (predominantly in the basal and subpleural regions of the 
lobes), activated myofibroblasts accumulation (in subepithelial fibroblastic foci), 
and ECM deposition (collagen and fibronectin) (32).  New vessels are formed 
around fibroblast foci and dysregulation in the balance of metalloproteases and 
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their inhibitors, tissue inhibitors of metalloproteinases (TIMPs).  This disruption in 
proteases and anti-proteases contributes to the deposition and accumulation of 
ECM, which ultimately occludes the airways rendering the damage to the alveoli 
irreversible.  Failure to regulate unwarranted fibro-proliferation and matrix 
deposition is at the core of treatment ineffectiveness.  New advancements need 
to be made in our understanding of the pathogenesis of IPF in order to develop 
novel and effective therapeutic interventions for this devastating disease.  This 
dissertation seeks to address this gap in knowledge. 
 The underlying mechanisms of fibrosis remain poorly understood.  IPF is a 
crippling disease where the progressive scarring of the lung tissue reduces gas 
exchange capacity.  The clinical course of IPF is characterized by an increased 
shortness of breath, a dry and hacking cough, decreased exercise capacity, 
fatigue and malaise (feeling of being unwell), clubbing (widening of tips of fingers 
and toes), and ultimately death due to respiratory failure (32).   In addition, other 
medical conditions can arise secondary to IPF.  Such potentially life-threatening 
conditions include blood clotting and infections in the lung, collapsed lungs, lung 
cancer, and heart and respiratory failure resulting from pulmonary hypertension 
(32).  Epithelial damage, tissue injury, and inflammation are involved in the 
development of IPF; however, no clinical benefits have been obtained using anti-
inflammatory therapy.  A key cytokine that has been established to promote 
fibrosis is transforming growth factor (TGF-β) (33).  TGF-β signaling via the 
Smad3 pathway is critical for the progression of pulmonary fibrosis (34).  In 
addition, Smad2 activation by TGF-β1 induces EMT in human A549 alveolar 
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epithelial cells (35). Similar EMT induction by TGF-β has been observed in 
primary alveolar epithelial cells, which suggest this process may be a possible 
source of myofibroblasts in IPF (36).  Different mediators are thought to play an 
important role in pulmonary fibrosis, such as TNFα, CTGF, PDGF, endothelin, IL-
1β, GM-CSF, IL-10, and important to this thesis, IL-6 (37, 38).  TGF-β appears to 
play a central role in the development of pulmonary fibrosis since it is necessary 
and sufficient to cause fibrotic lung disease in mice (39).  Transgenic over-
expression of TGF-β in mice can promote the development of the chronic 
progressive nature of pulmonary fibrosis, allowing for examination of drug effects 
on TGF-β pathways (33).  The most widely used animal model of pulmonary 
fibrosis is the bleomycin model.  Bleomycin is a glycosylated linear nonribosomal 
peptide antibiotic used as an anti-cancer treatment for lymphomas, such as 
Hodgkin’s disease (40).  Bleomycin is produced by the bacterium, Streptomyces 
verticillus, and its mechanism of action is through the induction DNA strand 
breaks (40).  Since the lungs lack the cysteine protease enzyme bleomycin 
hydrolase, the most serious complication of bleomycin use is pulmonary fibrosis.  
In animal models, bleomycin induces fibrotic changes similar to human disease 
(i.e. patchy parenchymal inflammation, epithelial cell injury with reactive 
hyperplasia, and interstitial and intra-alveolar fibrosis) producing different 
patterns of fibrotic lesions depending on dose and route of application (40).  
Single doses of bleomycin via intratracheal (i.t.) administration produce reversible 
subchronic changes, representing an acute model of lung injury.  However, 
repeated doses of bleomycin lead to long-term tissue damage.  Intraperitoneal 
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(i.p.) injections of bleomycin in mice produce subpleural scarring, whereas i.t. 
installations lead to fibrotic changes in a bronchiolocentric accentuated manner 
(40). The disadvantages of this i.t. bleomycin model include the connection with 
inflammation, which complicates how to differentiate between pro-inflammatory 
from pro-fibrotic activities, and the production of reversible fibrosis, which 
correlates poorly to human disease (40).  However, repeated i.p. doses of 
bleomycin in mice produces changes that resemble the progressive and chronic 
nature of pulmonary fibrosis observed in humans.  This rodent model is an 
excellent tool to investigate fibrotic disorders in order to discover novel 
treatments for these deadly diseases.    To ensure that our findings in these 
models are relevant to human disease, it is crucial to validate our findings directly 
on human tissue to discover novel pathways that are involved in the regulation of 
these fibroproliferative lung diseases and to achieve effective therapeutic 
intervention.  Hence, this dissertation will focus on addressing the role of 
adenosine and IL-6 in the development of adenosine-mediated pulmonary 
fibrosis. 
 
ADENOSINE METABOLISM AND SIGNALING 
Adenosine is a signaling molecule that is generated following cellular 
injury and is able to promote tissue protection and repair through increasing the 
oxygen supply/demand ratio, enhancing anti-inflammatory properties, and 
stimulating angiogenesis (41).  Upon cellular stress and damage, ATP is 
released into the extracellular space through poorly understood mechanisms. 
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Extracellular ATP interacts with P2 purinergic receptors to serve as a signaling 
molecule (Fig 1.1).  In addition, ATP can be rapidly dephosphorylated to form 
extracellular adenosine.  This process is mediated by extracellular nucleotidases, 
namely CD39 and CD73.  Extracellularly, adenosine is generated via the apyrase 
(CD39), which dephosphorylates ATP and ADP to form AMP (42), and the ecto-
5’-nucleotidase (CD73), which dephosphorylates 5’-AMP to form adenosine (43).  
Therefore, CD73 plays an important role in the regulation of local adenosine 
production.  Intracellularly, adenosine is generated via the cytosolic 5’ 
nucleotidases (CD73) (44) and through S-adenosylhomocysteine hydrolase (45).  
Extracellular adenosine can be transported inside the cell by the equilibrative and 
concentrative nucleoside transporters (ENTs and CNTs, respectively) (46, 47).  
Inside the cell, adenosine can be either catabolized to inosine by the enzyme 
adenosine deaminase (ADA) or re-phosphorylated into AMP, ADP, and ATP by 
adenosine kinase (AK) (48).  Alternatively, AMP can be phosphorylated back to 
ATP or deaminated to inosine 5’-monophosphate (48) and ammonia by AMP 
deaminase.  Under normal conditions, the concentration of adenosine is 
maintained in a steady state by cyto5’NT, AK, and ADA.  Hence, at conditions of 
permanent cellular injury, adenosine concentrations increase by the massive 
release of ATP from the cell and its subsequent dephosphorylation by CD39 and 
CD73.  At the same time, cellular damage induces a rapid increase in 
intracellular adenosine levels, which inhibits AK and overwhelms ADA (49).  In 
turn,  changes  in  adenosine  concentration  regulate  an  array  of  physiological  
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Figure 1.1 
 Adenosine Metabolism and Signaling.  In response to stress, adenosine 
(Ado) is generated as the result of ATP catabolism.  Adenosine deaminase 
(ADA) deaminates adenosine into inosine (Ino).  ATP is dephosphorylated by 
extracellular nucleotidases (ecto5’NT) such as CD39 and CD73 to form 
extracellular Ado. Adenosine mediates its effect through four G-protein coupled 
receptors (AdoR), which are coupled to effector molecules that regulate second 
messenger systems.  Intracellular Ado is produced by dephosphorylating AMP 
(cyto5’NT) or the hydrolysis of S-adenosylhomocysteine (SAH).  Intracellular Ado 
can be secreted or be phosphorylated back to ATP by adenosine kinase (AK). 
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processes by engaging the cell surface adenosine receptors, which lead to 
modulations in intracellular cAMP and Ca++ resulting in either tissue-protective or 
tissue-destructive effects.  
Adenosine levels are elevated in the lungs of humans and mice with 
chronic lung diseases (50, 51).  Adenosine signals through the engagement of 
cell surface G-protein coupled receptors (A1R, A2AR, A2BR, and A3R), which are 
also altered in the lungs of patients with chronic lung disease.  Adenosine 
receptors exert their action by either stimulating (Gαs, A2AR and A2BR) or 
inhibiting (Gαi, A1R and A3R) adenylate cyclases and production of the second 
messenger cAMP (52).  Additionally, the A2BR, and A3R are coupled to Gαq, 
which activates phospholipases (53, 54).   Adenosine under normal conditions 
can elicit tissue protective pathways to promote healing in response to injury.  
These pathways include the inflammatory response, matrix deposition, and 
angiogenesis.  The activation and effect of these pathways are subject to 
variation depending on the host genetic composition and the environment.  
Dysregulation of factors, such as adenosine, can disrupt the pathways that 
regulate the balance between healing or progression to disease.  Excessive 
adenosine production, such as that found in hypoxic environments of the 
inflamed lung, can promote mast cell degranulation, induce bronchoconstriction, 
and exacerbate tissue injury (55-59).  Thus, through poorly understood 
mechanisms, elevations in adenosine lead to diverse actions on inflammation, 
tissue injury, and tissue remodeling in chronic lung diseases.   
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Adenosine deaminase (ADA) is the enzyme responsible for the 
deamination of adenosine to inosine.  Hence, ADA regulates adenosine levels in 
tissues and in cells.  Our lab has genetically engineered mice that lack the gene 
for ADA (Ada-/- mice), in which adenosine levels increase progressively.  These 
mice develop pulmonary phenotypes similar to that seen in patients with chronic 
lung disease, such as alveolar airspace destruction, and pulmonary inflammation 
and fibrosis (60).  Studies in Ada-/- mice show that elevations in lung adenosine 
are sufficient to cause lung inflammation and damage.  Furthermore, this 
pulmonary phenotype can be prevented and reversed by lowering adenosine 
levels with ADA enzyme replacement therapy (61).  This makes Ada-/- mice an 
excellent model for examining the mechanisms of adenosine driven lung disease.  
In this model, at the stage of acute tissue injury and low adenosine 
concentrations, high affinity adenosine receptors (A1R, A2AR) are engaged and 
exert anti-inflammatory and tissue protective pathways (62, 63).  However, in the 
setting of prolonged tissue injury and increased levels of adenosine, low affinity 
adenosine receptors (A2BR, A3R) activate pro-inflammatory and tissue destructive 
pathways (62, 63) contributing to the pathology and progressive nature of chronic 
lung disease.  In addition, during the acute phase of lung injury the A2BR can also 
provide protective functions despite its low affinity and at low adenosine 
concentrations (64).  Furthermore, mouse models of lung injury, such as 
transgenic mice overexpressing IL-13 (65) and IL-4 (66), develop pulmonary 
inflammation, alveolar airspace enlargement, and fibrosis in association with 
increased adenosine levels.  Similarly, the mouse model of bleomycin-induced 
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pulmonary fibrosis exhibits increased adenosine concentrations.  Consequently, 
lowering adenosine levels in these models also prevents and reverses features 
of pulmonary disease (64, 66, 67).  Collectively, these studies suggest that 
elevations of adenosine regulate pathways that promote the pathogenesis and 
the chronic pathobiology of lung diseases.  However, the detailed mechanisms 
involved are not known. 
 
ADENOSINE AND LUNG DISEASES 
It has been established that adenosine concentrations and receptor levels 
are elevated in patients with chronic lung disease (68).  Furthermore, adenosine 
elevation in these patients has been associated with increased inflammation and 
fibrotic foci development (69).  The first link between adenosine and pulmonary 
disease in humans was made when it was shown that adenosine elicits 
bronchoconstriction in asthmatic patients but not in normal patients (70).  This 
observation suggested that adenosine signaling is altered in pulmonary diseases.  
Adenosine therapeutics have been shown to be beneficial as an anti-asthmatic 
treatments, namely by theophylline-induced inhibition of adenosine receptors 
(71).  Theophylline, a methyl xanthine, inhibits phosphodisterase (PDE) at high 
concentrations mediating bronchodilatory effects; whereas at low concentrations, 
theophylline acts as an adenosine receptor antagonist mediating 
immunoregulatory functions (72).  Theophylline, a non-specific adenosine 
receptor antagonist, provides therapeutic benefit by reducing inflammation via 
adenosine antagonism.  Taken together, these observations imply that 
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adenosine has pro-fibrotic or pro-inflammatory effects, depending on the receptor 
signaling profile and the source of injury.  Our lab operates based on the 
hypothesis made from these observations, namely that adenosine regulates 
pathways that contribute to the pulmonary pathology seen in chronic lung 
disease.  My thesis focuses on one potential mechanism, which involves the pro-
fibrotic mediator IL-6. 
 
ADENOSINE AND IL-6 
Adenosine signaling plays an important role in the regulation of fibrosis, 
but the mechanisms by which this occurs are not known.  Part of the goal of this 
thesis is to determine the mechanisms by which adenosine regulates features of 
chronic lung disease.  One potential mechanism is the regulation of IL-6 
production, a pro-fibrotic cytokine.  Adenosine regulates the production of this 
pleiotropic cytokine in numerous cell types, including airway epithelial cells (73), 
intestinal epithelial cells (74), pituitary folliculostellate cells (75), astrocytes (76), 
cardiomyocytes (77), and peritoneal macrophages (78), through the engagement 
of the A2BR (79).  Treatment of astroglioma cells with a non-specific adenosine 
agonist is also able to increase IL-6 mRNA and protein levels (80).  In addition, 
adenosine induces IL-6 secretion during active inflammation in the intestinal 
lumen of mice (81).   Also, adenosine is able to stimulate IL-6 production in 
various cells found in the lung, including bronchial smooth muscle cells (82), 
alveolar macrophages (83), and lung fibroblasts (28).  Thus, there is strong 
experimental evidence that adenosine regulates IL-6 production. 
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IL-6 enhances the innate immune system and protects against tissue 
damage by inducing an acute phase reaction (84).  Besides its functions in 
inflammation and the acute-phase response, IL-6 plays an important role in 
haematopoiesis, liver and neuronal regeneration, and B and T cell growth and 
differentiation (85).  IL-6 is released in response to cytokine induction such as IL-
1 and TNF-α (86, 87).  In response to injury and infection, IL-6 is produced by 
different cells such as, mast cells, eosinophils, endothelial cells, smooth muscle 
cells, monocytes/macrophages, and B and T cells (88).  In addition, IL-6 is able 
to induce autoimmunity, amplify acute inflammation, and promote chronic 
inflammation (89).  Dysregulation of IL-6 signaling has been implicated in the 
onset and maintenance of several diseases, such as multiple sclerosis, 
inflammatory bowel disease, rheumatoid arthritis, and cancer (90).  Strong 
evidence provided by animal models indicates that inhibition of IL-6 represents a 
promising therapeutic approach for many inflammatory and autoimmune 
diseases and some cancers (10).  The first humanized monoclonal antibody 
(mAb) targeting IL-6 receptor, Tocilizumab or Actemra, was developed by the 
Japanese company Chugai (91).  This IL-6 inhibitor has been approved and 
shown to be beneficial for the treatment of Castleman’s disease and rheumatoid 
arthritis.  Several anti-IL-6 and anti-IL-6Rα mAbs and alternatively native IL-6 
blockers (sgp130Fc) are currently under development in different clinical and 
preclinical studies (10, 91, 92).  However, the effectiveness of such therapies has 
not been considered for the treatment of chronic lung diseases.   
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IL-6 SIGNALING 
IL-6 belongs to the IL-6 family of cytokines, which includes interleukin-11 
(IL-11), interleukin-27 (IL-27), ciliary neurotrophic factor (CNTF), cardiotropin-1 
(CT-1), cardiotropin-like cytokine (CLC), neuropoietin (NPN), leukemia inhibitory 
factor (LIF), and oncostatin M (OSM).  Each member of this IL-6 cytokine family 
binds to its own or similar receptor subunit; for instance, IL-6 binds the 80 kDa IL-
6 binding type I transmembrane glycoprotein termed the membrane bound IL-6 
receptor-α (mIL-6Rα, CD126).  In addition, the IL-6 cytokines family share a 
common receptor component, the type I transmembrane signal transducing unit 
known as gp130 (CD130) (93).  The IL-6Rα and gp130 form the IL-6 receptor 
complex.  The mIL-6Rα subunit is expressed restrictively in certain cells while 
gp130 is ubiquitously expressed (94).  However, cells that lack the mIL-6R-α can 
still be activated via a soluble version of the receptor.  Thus, the soluble IL-6 
receptor (sIL-6Rα) can be bound by ligand and subject a wide variety of cell 
types functional to IL-6 signaling.  This alternative mechanism of IL-6 activating 
cells lacking the mIL-6Rα is termed IL-6 trans-signaling (Fig 1.2).  Soluble gp130 
acts as an endogenous inhibitor of IL-6 trans-signaling by preventing the 
activation of target cells since it sequesters the IL-6 and sIL-6Rα complex.  
Initially, IL-6 binds with low affinity to the IL6-Rα forming a heterodimeric 
complex with high affinity towards gp130, which consequentially forms a 
trimolecular complex upon binding.  Hence, a hexameric signaling complex is 
formed by the assembly of two trimolecular complexes consisting of IL-6, IL-6Rα, 
and gp130 (95).  The gp130 cytoplasmic domain, at tyrosine residue 683 (Y683),  
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Figure 1.2 
IL-6 Signaling Pathway.  IL-6 signals through the binding of its receptor, which 
is composed of two subunits, an alpha subunit for ligand specificity (IL-Rα) and a 
signal transducing subunit (gp130) that is shared with other cytokines in the IL-6 
family.  Upon receptor binding, activation of JAK kinases is followed.  JAK 
kinases are responsible for phosphorylating and activating STAT transcription 
factors, particularly STAT-3.  Once STAT-3 is phosphorylated, then it undergoes 
dimerization and it is translocated into to the nucleus in order to activate 
transcription of target genes through their STAT-3 response elements.  Classical 
signaling is mediated via the membrane bound IL-6 receptor α (mIL-6Rα).  IL-6 
trans-signaling refers to the activation of cells that lack the mIL-6Ra.  Activation 
of these cells is mediated via the soluble IL-6 receptor a (sIL-6Ra), which can be 
produced systemically by alternative splicing or locally by proteolytic cleavage.  
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associates with the Janus Kinases (96), namely Jak1, Jak2, and Tyk2.  The IL-6 
hexameric complex institutes a gp130 conformational change bringing these non-
receptor kinases into close proximity.  Upon activation, JAKs transactivate each 
other by phosphorylating tyrosine residues, which can be recognized by Src 
homology 2-containing tyrosine phosphotase (SHP-2) and signal transducer and 
activator of transcription (STATs).  In addition, SHP-2 recruitment requires gp130 
phosphorylation in order to enhance IL-6 signal transduction (97).   
Upon IL-6 activation, the phosphorylation of the tyrosine residues of the 
gp130 cytoplasmic domain determines the sequential downstream pathways (Fig 
1.3).  For instance, at residue Y759 the ERK/MAPK cascade is activated 
primarily for cell survival, whereas at residue Y657, the Akt/PI3K pathway is 
initiated mainly to enhance proliferation (97, 98).  On the other hand, gp130 
cytoplasmic tyrosine residues, such as Y767, Y814, Y905, and Y915, can 
activate the STAT-3 pathway in an YXXQ motif dependent manner (97).  STATs 
are characterized by a transient activation with the receptors mediated by their 
SH2 domains.  Upon recruitment of a monomeric STAT to the receptor, 
phosphorylation ensues, leading the phosphorylated STATs to dimerize.  Once 
the STATs dimerize, they are translocated into the nucleus where they bind the 
STAT response elements found on the promoter region of target genes (97, 99).   
Thus, IL-6 signals by binding to the membrane bound IL-6 receptor (mIL-
6R-α), which is expressed predominantly on leukocytes and hepatocytes, and 
then associates with the signal-transducing gp130 protein in order to 
phosphorylate  and  dimerize  STAT-3  (84, 88).   Hence,  phospho-STAT-3  is an  
  
 
 
Figure 1.3 
STAT-3 Activation by gp130
transcription (100) family requires JAK
residues in the Src homology 2 domain.  JAKs phosphorylate gp130 at tyrosine 
residue Y683.  The gp130 signal transducing unit is able to activate the MAP 
Kinase (Y759) and the PI3K pathway (Y657). 
residues Y767, Y814, Y904, and Y915 is able to induce STAT
STAT-3 activation is dependent on the motif YXXQ and tyrosine residues Y705 
and S727, which induces dimerization and translocation to the nucleus, 
respectively.  STAT-3 target genes are associated with cell cycle progression, 
inhibition of apoptosis, and oncogenes, including p19, c
 
.  The signal transducers and activators of 
-dependent phosphorylation of tyrosine 
 Phosphorylation of gp130 at 
-3 phosphorylation.  
-myc and bcl
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indicator of IL-6-induced cellular activation.  Phosphorylated STAT-3, once 
dimerized, is translocated into the nucleus to act as a transcription factor and 
regulates the expression of target genes (89, 90, 101).   
In addition to this classical pathway, IL-6 binds to the soluble IL-6 receptor 
(sIL-6Rα) to provide an alternative mechanism of gp130 activation for cells that 
lack the mIL-6Rα (85, 102).  This trans-signaling mechanism increases the 
spectrum of IL-6 activities from immune responses to involvement of chronic 
pathological states (Fig 1.2).  This soluble version of the mIL-6Rα lacks the 
transmembrane and cytoplasmic domains, is found at basal levels of 25-35 ng/ml 
in BAL from healthy individuals (103), and there are two isoforms generated by 
posttranscriptional or posttranslational processes (104).  Posttranscriptionaly, the 
sIL-6Rα can be produced by alternative splicing (10%) (105) and 
postranslationaly, by ectodomain shedding (90%) (106).  Alternative spliced sIL-
6R-mRNA codes for a reading frame shift that generates a novel carboxy 
terminal protein sequence (GSRRRGSCGL) (107).  The ectodomain proteolysis 
of the mIL-6Rα is produced by the A Disintegrin And Metalloproteinases (108) 
gene family members of metalloproteases, such as ADAM10 and ADAM17 (107).  
ADAM17 is also known as Tumor Necrosis Factor-α Converting Enzyme (TACE), 
which cleaves membrane bound TNFα thereby activating it (109).  The mIL-6Rα 
is targeted by both ADAM10, which is involved in constitutive shedding (110), 
and by ADAM17, which is involved in stimulated shedding.  Under 
pathophysiological conditions, stimulated shedding is thought to be a master 
regulator of sIL-6Rα generation and IL-6 trans-signaling initiation (111).  
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ADAM17 cleaves the mIL-6Rα close to the transmembrane region, between 
amino acid position Q357-D358, releasing the sIL-6Rα into the extracellular 
space while the short C-terminal remains in the plasma membrane (108).  
Accordingly, it has been shown that sIL-6R elevation regulates both innate and 
acquired immunity (98) and dysregulation of this pathway leads to various  
pathological conditions, since its elevations have been reported in cancer and 
several chronic inflammatory and autoimmune diseases (112).  However, IL-6 
trans-signaling has not been investigated in chronic lung diseases.  In this 
dissertation, I will address the role of IL-6 in pulmonary pathologies and trans-
signaling in the regulation of fibrosis. 
 
IL-6 IN LUNG DISEASES 
As an inflammatory cytokine, IL-6 is involved in the pathogenesis of lung 
diseases such as asthma and COPD (113, 114), and elevated IL-6 correlates 
with disease progression and severity.  Evidence to support the involvement of 
IL-6 in chronic lung diseases include the observation that alveolar macrophages 
isolated from asthmatic patients exposed to allergen demonstrate increased IL-6 
secretion (115).  In addition, IL-6 expression is observed in mast cells (116) and 
bronchial epithelial cells (117) from asthmatics, and IL-6 elevations are detected 
in BALF and sputum from asthmatics (118).  In addition, over-expressing IL-6 in 
lung epithelial cells results in massive airway inflammation (119).  In contrast, IL-
6 is able to diminish airway responsiveness when lung epithelial cells over-
expressing IL-6 are challenged with methacholine, which mimics histamine 
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effects (120).  It is well established that IL-6 is an important cytokine with the 
ability to act as a pro- or anti-inflammatory or pro-fibrotic agent depending on the 
environment, and the source and extent of injury.  IL-6 is elevated in the lungs of 
patients suffering from chronic lung diseases; however, its role in these diseases 
is still being determined.    
As a fibrotic cytokine, IL-6 increased expression is associated with fibrotic 
lung diseases, such as sarcoidosis and IPF (121).  Patients with systemic 
sclerosis and IPF have increased IL-6 levels in their lungs (122).  In addition, 
bleomycin-treated mice exhibit IL-6 elevations during chronic stages of disease 
(123).  Furthermore, IL-6 is able to induce fibrotic effects (122).  IL-6-deficient 
mice exposed to bleomycin exhibit reduced fibrosis compared to control mice 
(124).  IL-6 is able to induce myofibroblast differentiation (28) and collagen 
synthesis from fibroblasts (125).  Also, the severity of pulmonary fibrosis 
correlates with increased levels of sIL-6Rα (125).  In addition,  fibroblasts 
isolated from IPF patients treated with IL-6 are apoptosis-resistant and show 
enhanced proliferation (126).  Hence, these studies demonstrate that IL-6 acts as 
a pro-fibrotic cytokine in pulmonary fibrosis.  However, the mechanism by which 
IL-6 contributes to pulmonary fibrosis remains elusive.  This thesis will establish a 
novel link between adenosine, IL-6, and pulmonary fibrosis. 
 
DISSERTATION OVERVIEW 
In this dissertation I will address the gap in knowledge between the IL-6 
signaling pathway and adenosine-mediated pulmonary injury.  The pulmonary 
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phenotype observed in Ada-/- mice demonstrates its utility for examining the 
mechanisms by which adenosine regulates features of chronic lung disease.  
Previous studies have demonstrated that elevated levels of adenosine leads to 
increased production of IL-6 mRNA and protein in the lungs of Ada-/-  mice via 
engagement of the A2BR (79). Given the ability of IL-6 to perpetuate the chronic 
state of various inflammatory diseases, I hypothesize that elevations of IL-6 
regulates features of fibrosis in models of adenosine-dependent pulmonary 
injury.  In this thesis, I will present three chapters in which I first examine the role 
of IL-6 in an adenosine-driven model, namely Ada-/- mice, using genetic and 
pharmacological approaches.  To enhance IL-6 relevance in the pulmonary injury 
and fibrosis observed in Ada-/- mice, in the next chapter I will extend these 
findings using the same approaches (i.e. genetic and pharmacologic) to a more 
conventional model of pulmonary fibrosis, the bleomycin model.  The results from 
these experiments demonstrate that the genetic removal or neutralization of IL-6 
leads to an improvement of pulmonary phenotypes in both models.  This 
suggests that IL-6 is responsible for some key features of pulmonary 
inflammation and fibrosis.  In the process, I determine that phospho-STAT-3 is 
activated in epithelial cells in the lung, which leads to my description in the last 
chapter of the potential regulatory mechanisms involve in fibrosis.  The IL-6-
dependent activation of alveolar epithelial cells (AECs) in both models suggests 
that IL-6 trans-signaling may play a role in activating AECs and regulating 
fibrosis.  One of the key processes for driving fibrosis, namely EMT, can be 
directly driven by IL-6.  Thus, I found evidence that IL-6 trans-signaling was able 
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to induce and enhance EMT in vitro.  Finally, these observations from animal and 
cellular models are significant for human disease.  I demonstrate that these 
pathways are elevated in samples collected from patients with COPD and IPF in 
a similar manner as in our animal models.  In this dissertation, these findings 
demonstrate that adenosine-dependent elevations of IL-6 contribute to the 
development and progression of pulmonary inflammation and fibrosis.  Hence, 
the IL-6 signaling mechanism represents a potential therapeutic target for these 
deadly disorders.  Thus, this study has enabled the identification of signaling 
pathways employed in the exacerbation of pulmonary phenotypes in chronic lung 
diseases.   
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CHAPTER TWO 
EXPERIMENTAL METHODS 
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GENERATION AND GENOTYPING MOUSE LINES 
Ada-/- mice were generated and genotyped as described previously (60, 
127).  Mice homozygous for the null Ada allele were designated ADA-deficient 
(Ada-/-), while mice heterozygous for the null Ada allele were designated as ADA-
competent mice (Ada+).  All mice were on a mixed 129/C57BL/6J background, 
and all phenotypic comparisons were performed among littermates.  In addition, 
IL-6-deficient mice congenic on the C57BL/6J background were obtained from 
Jackson Laboratory (Bar Harbor, ME, USA).  Animal care was in accordance with 
institutional and NIH guidelines. The University of Texas Health Science Center 
at the Houston Animal Welfare Committee in Houston, Texas, USA reviewed and 
approved these studies.  Mice were housed in ventilated cages equipped with 
microisolator lids and maintained under strict containment protocols. 
 
GENERATION OF DOUBLE KNOCK-OUT MICE 
To generate ADA/IL-6 double knockout mice (Ada/IL-6-/-), IL-6-deficient 
mice congenic on a C57BL/6J background (Jackson Laboratory, Bar Harbor, ME, 
USA) were backcrossed with Ada-/- mice also congenic on the C57BL/6J 
background.  Wild type C57BL/6J mice were purchased from Harlan.  All 
phenotypic comparisons were performed among littermates.  Animal care was in 
accordance with institutional and NIH guidelines.  These studies were reviewed 
and approved by the University of Texas Health Science Center at the Houston 
Animal Welfare Committee in Houston, Texas, USA.  
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ADA ENZYME THERAPY 
Polyethylene glycol-modified ADA (PEG-ADA) was generated by the 
covalent modification of purified bovine ADA with activated polyethylene glycol as 
described (64).  Ada-/- mice were identified at birth by screening for ADA 
enzymatic activity in the blood as described previously (64).  Ada-/- mice were 
maintained on ADA enzyme therapy from postnatal day 1 until postnatal day 25.  
Ada-/- mice received intra-muscular (i.m.) injections of PEG-ADA on postnatal 
days 1, 5, 9, 13, and 17 (0.625 Units, 1.25 Units, 2.5 Units, 2.5 Units, and 2.5 
Units, respectively) and intra-peritoneal (i.p.) injections on postnatal days 21 and 
25 (5 Units each).  Mice were sacrificed on day 27 after the last PEG-ADA 
injection (postnatal day 43).  In addition, ADA/IL-6 double knock out mice were 
subjected to ADA enzyme therapy until postnatal day 25 and sacrificed on 
postnatal day 43, 27 days after treatment. 
 
INTRAPERITONEAL BLEOMYCIN TREATMENT 
IL-6-competent or IL-6-deficient male mice congenic on C57BL/6J 
background (Jackson Laboratory, Bar Harbor, ME, USA) 5-weeks old were 
treated with 0.035 U/g bleomycin (Teva Parenteral Medicines).  PBS was used 
as vehicle and as control.  Bleomycin treatment was administered twice a week 
for four weeks via intra-peritoneal (i.p.) injections in 100 µl volume (128).  Mice 
were harvested on day 33 post-treatment. 
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IL-6 NEUTRALIZATION ASSAY: 
IN ADA-DEFICIENT MICE AND BLEOMYCIN MODEL 
 
Treatments with an IL-6 antibody (30 mg/kg) or control (PBS/isotype 
antibody/no treatment) were initiated on postnatal day 26.  Treatments consisted 
of subcutaneous injections in 100 µl volume on postnatal day 26, 31, and 37.   
Treatment groups included Ada+ mice or Ada-/- mice receiving an anti-IL-6 
antibody, isotype antibody, PBS (vehicle), or no treatment.  All mice were 
littermates, and both males and females were included in these experiments.  In 
separate experiments, C57BL/6J male mice subjected to intraperitoneal 
bleomycin administration (twice a week for four weeks, 0.035 U/g bleomycin in 
100 µl each injection) were treated with an IL-6 antibody (30mg/kg in 100 µl 
volume subcutaneous injections) at day 15, 19, 23, and 27 after first bleomycin 
injection.   Blood was collected using EDTA as an anticoagulant and centrifuged 
at 1200 rpm for 20 min to obtain plasma.  BAL fluid was collected as described 
previously and was centrifuged to remove cells.  Plasma and the BAL fluid 
supernatants were analyzed using an ELISA kit to determine exposure levels of 
the anti-IL-6 antibody.   
 
HISTOLOGY, BRONCHIAL ALVEOLAR LAVAGE  
AND CELLULAR DIFFERENTIALS 
 
Mice were anesthetized with 2.5% avertin.  The trachea was cannulated 
and the lungs were lavaged four times with 0.3 ml of PBS (0.95–1 ml lavage fluid 
recovered). Total cell counts were determined using a hemocytometer, and 
aliquots were cytospun onto microscope slides and stained with Diff-Quick (Dade 
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Behring) for cellular differentials.  After lavage, the lungs were infused with 10% 
buffered formalin at 25 cm of H2O pressure and fixed overnight at 4°C.  Fixed 
lung samples were dehydrated and embedded in paraffin, and sections (5 µm) 
were collected on microscope slides and stained with H&E (Shandon-Lipshaw) or 
Masson’s Trichome (EM Science) according to the manufacturer’s instructions. 
 
IMMUNOSTAINING ON MOUSE LUNG SECTIONS 
Immunohistochemistry was performed on 5 µm sections cut from formalin-
fixed, paraffin-embedded lungs. Sections were rehydrated through graded 
ethanols to water, endogenous peroxidases were quenched with 3% hydrogen 
peroxide, antigen retrieval was performed (Dako) for 30 min at 95°C, and 
endogenous avidin and biotin was blocked with the Biotin-Blocking System 
(Dako).  Slides were incubated with primary antibodies for mouse IL-6 (1:200 
dilution, 1 hr room temperature, Abcam), phospho-STAT-3 (1:100 dilution, 4°C 
overnight, Abcam), or α-SMA (1:1000 dilution, 4°C overnight, mouse monoclonal, 
Sigma-Aldrich).  All sections were incubated with ABC Elite Streptavidin reagents 
and appropriate secondary antibodies.  Sections were developed with 3,3′-
diaminobenzidine (Sigma-Aldrich) and counterstained with methyl green or 
hematoxylin.  For α-SMA staining, slides were processed with the Mouse on 
Mouse Kit and the Vector Red Alkaline Phosphatase Substrate Kit (Vector 
Laboratories).   
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IMMUNOFLUORESCENCE ON MOUSE LUNG SECTIONS 
Sections were rehydrated and fixed with acetone and methanol.  
Endogenous fluorescence was quenched with 1% NaBH4 for 30 min at room 
temperature.  Slides were incubated with primary antibody to fibronectin (1:400 
dilution, 1 hr room temperature, rabbit polyclonal, Sigma-Aldrich) followed by 
secondary antibody (1:1000 dilution, 1 hr room temperature, donkey anti-rabbit 
IgG Alexa fluor 555-red, Invitrogen).  Sections were covered with Vectashield 
anti-fade medium with DAPI (VectorLabs). 
 
MEAN CHORD LENGTH DETERMINATION 
The size of alveolar airspaces was determined in pressure-infused lungs 
by measuring mean chord lengths on H&E-stained lung sections (79). 
Representative images were digitized, and a grid consisting of 53 black lines at 
10.5 µm intervals was overlaid on the image. This line grid was subtracted from 
the lung images using Image-Pro Plus image analysis software (version 2.0; 
MediaCybernetics), and the resultant lines were measured and averaged to give 
the mean chord length of the alveolar airspaces. The final mean chord lengths 
represent averages from 10 non-overlapping images of each lung specimen. All 
quantitative studies were performed blinded with regard to animal genotype. 
 
QUANTITATIVE REAL TIME RT-PCR 
Mice were anesthetized, and the lungs were rapidly removed and frozen in 
liquid nitrogen.  Total RNA was isolated from frozen whole-lung tissue using 
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TRIzol reagent (Invitrogen).  RNA samples were then DNase treated and 
subjected to quantitative real-time RT-PCR. The primers, probes, and 
procedures for real-time RT-PCR were described previously (79).  Specific 
transcript levels for IL-6, CXCL-1, CCL2 (MCP-1), osteopontin (OPN), IL-17, 
CXCL-2 (MIP-2), TNF-α, TIMP-1, MMP-9, MMP-12, CLCA-3, fibronectin, and α1-
procollagen were determined by normalization to 18S rRNA and presented as 
mean normalized transcript levels using the comparative Ct method (2∆∆Ct). 
Primer sequences for the transcripts examined were the same as previously 
used (63, 64, 79).  
 
PROTEIN ANALYSIS 
TIMP-1 and sIL-6Rα protein levels in BAL fluid were assessed using an 
ELISA kit (R&D Systems) according to the manufacturer’s instructions. 
 
WESTERN BLOT ANALYSIS 
Frozen lungs were homogenized and lysed on ice with protein lysis buffer 
(1 M Tris (pH7.4), 1 M NaCl, 1% Triton X-100) freshly supplemented with 1X 
protease inhibitor mixture (Roche Diagnostics). A 50 µg portion of total protein 
was electrophoresed on 10% SDS PAGE gels and transferred overnight at 4°C 
to Immobilon-P polyvinylidene difluoride (Millipore), and western blotting was 
performed.  For cell culture, 15 µg of total protein was loaded for SDS-PAGE.  
For primary antibody detection (overnight at 4°C), a rabbit polyclonal anti-mouse 
was used against phospho-STAT-3 (Abcam 1:500), STAT-3 (Abcam 1:500), α-
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SMA (Sigma 1:500), TWIST (Santa Cruz 1:500) and vimentin (Santa Cruz 
1:500), while a mouse monoclonal anti-human was used against e-cadherin 
(Invitrogen, 1:500), α-actin (Sigma 1:5,000), and GAPDH (Invitrogen 1:1,000).  
Secondary HRP-conjugated antibodies (eBioscience) were applied for 1 hour at 
room temperature (for P-STAT-3, STAT-3 in 1:1,000; for α-SMA, TWIST, 
vimentin, e-cadherin, and GAPDH at 1:2,000; and for α-actin at 1:10,000).  
Signals were detected by chemiluminesce (Pierce Chemical).  Using ImageJ 
analysis, phospho-STAT-3 band intensity was quantified from four different blots. 
 
MEASUREMENT OF VASCULAR PERMEABILITY  
Lung vascular permeability was quantified from Ada-/- mice and competent 
mice treated with anti-IL-6 or isotype antibody via subcutaneous injections in 100 
µl volume on postnatal day 26, 31, and 37 (as previously performed).  At 
postnatal day 43, these different treatment groups were subjected to intra-
peritoneal (i.p.) administration of Evans blue dye (0.2 ml of 0.5% in PBS) (129).  
Four hours later after Evans blue dye administration, lungs were perfused with 
PBS and harvested. Lung and heart Evans blue concentrations were quantified 
after formamide extraction (55°C overnight) by measuring OD610 with 
subtraction of reference OD at 450 nm.  Evans blue dye contents were 
determined through comparison to a standard curve generated from dye 
dilutions. 
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PAS MUCUS INDEX 
In separate experiments, Ada-/- mice were genotyped and not maintained 
on ADA enzyme therapy, which develop pulmonary phenotypes by postnatal day 
18 and 21, which subsequently die due to pulmonary failure.  ADA-competent 
and Ada-/- mice without PEG-ADA treatments were subjected to a single dose 
(s.c. in 100 µl) of IL-6 antibody (30 mg/kg) or isotype antibody on postnatal day 
18.  These mice were harvested on postnatal day 21, their lungs were perfused, 
fixative with formalin, and paraffin embedded to generate lung sections.  Mucus 
production in bronchial airways was visualized by performing a periodic acid-
Schiff (PAS)-staining on lung sections and its quantification was determined 
using Image-Pro Plus analysis software (Media Cybernetics).  PAS-positive 
areas were selected from H&E lung sections using PhotoshopCS4 in order to 
determine the average pixel intensity from the digitized images.  In order to 
determine the mucus index, the following equation was employed: mucus index = 
(M x I) / A, where M stands for the area and I for the intensity of PAS-stained 
bronchial airways, and A stands for total epithelium.  These studies were 
conducted in a blinded manner, obtaining an average of 10 pictures from each 
lung to determine the mucus index. 
 
FIBROSIS ASSESSMENT 
To quantify the extent of fibrotic tissue damage, Ashcroft scores were 
determined on H&E-stained lung sections from Ada-/- mice and bleomycin model, 
with their respective control groups, under both approaches (IL-6 genetic removal 
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or neutralization).  The Ashcroft scores were determined as previously described 
(130).  These studies were conducted in a blinded manner on 6 mice per group, 
using 20 X magnification per section. 
 
COLLAGEN QUANTIFICATION 
The Sircol Collagen Assay (Biocolor Assays, Carrick, U.K.) was used to 
measure soluble collagen in BAL fluid (100 µl) according to the manufacturer’s 
instructions.   
 
MOUSE OXYGEN SATURATION MEASUREMENTS 
Physiological assessment measuring arterial oxygen saturation was 
conducted on conscious mice using the pulse MouseOx software analysis 
(STARR Life Sciences Corp).  Mice treated with bleomycin under the 
neutralization studies were subjected to the MouseOx.  The hair around the neck 
was removed from mice in order to use the collar clip light sensor.  The MouseOx 
provides real-time percent oxygen saturation of functional arterial hemoglobin by 
utilizing pulse oximetry measurements of light absorption from the red and 
infrared LEDs (Light Emitting Diodes).  Thus, pulse oximetry measurements of 
systemic arterial oxygen content are only obtained from pulsating blood, which 
can only be arterial since non-arterial blood does not change light absorption with 
heart rate.       
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IN VITRO STIMULATION OF ALVEOLAR EPITHELIAL CELL LINES 
Human alveolar epithelial cells, A549, and murine lung epithelial cells, 
MLE-12 and MLE-15, were obtained as a gift from Dr. Joe Alcorn, University of 
Texas Health Science Center at Houston.  Cells were cultured at 37°C with 5% 
CO2 in RPIM medium containing 10% FBS and 1% antibiotic (A549 and MLE-12) 
and antimycotic (MLE-15).  To test the role of IL-6 trans-signaling on EMT 
induction, these different cell lines (A549, MLE-12, and MLE-15) were subjected 
to treatment of: IL-6 alone (20 µg/µl), sIL-6Rα alone (20 µg/µl), and the IL-6/sIL-
6Rα complex (40 µg/µl total).  TGF-β (10 µg/µl) was used as a positive control in 
inducing EMT.  The media alone was used as a negative control.  In addition, the 
same treatments were performed but with the addition of a phospho-STAT-3 
inhibitor (100 µM) (131).  This inhibitor does not affect STAT-3 phosphorylation, 
rather inhibits phospho-STAT-3 DNA binding to target promoters.  After 
treatment, these cells were harvested at 24, 48, and 72 hrs post-treatment.  After 
photographing the effects of the different treatment with a inverted bright field 
microscope, these cells were subjected to western blotting using a RIPA lysis 
buffer or immunofluorescence using cover slips or chamber slides.   
 
HUMAN LUNG TISSUE AND BAL SAMPLES 
The University of Texas Health Science Center at Houston Committee for 
the Protection of Human Subjects reviewed and approved the use of human 
material conducted in this study.  All samples collected were already deidentified 
and exempted, thus providing no ethical concerns.  The Lung Tissue Research 
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Consortium (LTRC) at the National Institute of Heart Lung and Blood provided us 
with lung tissue samples from patients of COPD, Stage 0 and Stage 4, and IPF, 
mild and severe.  The LTRC classified the conditions of these patients based on 
spirometry, pathological examination, and high resolution CT scan.  Stage 0 
COPD and mild IPF demonstrated preserved lung functions based on the forced 
expiratory volume in one second (FEV1) and force vital capacity (FVC).  Based 
from these assessments, Stage 0 COPD (FEV1 >80%) and mild IPF (FVC 
>80%) were used as control groups compared to Stage 4 COPD (FEV1 <50%) 
and severe IPF (FVC <50%).  In addition, BAL samples from COPD and IPF 
patients were obtained through the collaboration with Dr. Murthy, University of 
Texas Health Science Center at Houston. 
 
STATISTICS 
Values are expressed as mean ± SEM.  As appropriate, groups were 
compared by analysis of variance; follow-up comparisons between groups were 
conducted using 2-tailed Student’s t test. A P value of ≤ 0.05 was considered to 
be significant. 
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CHAPTER THREE 
THE ROLE OF IL-6 IN ADENOSINE-
MEDIATED PULMONARY INJURY 
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INTRODUCTION 
ADENOSINE DEAMINASE-DEFICIENT MODEL 
Ada-/- mice are a useful model for examining the role of key mediators of 
lung disease that are driven by increased adenosine levels.  Work in Ada-/- mice 
suggests that elevated adenosine is sufficient to cause severe pulmonary 
pathology, which spontaneously develops as adenosine levels progressively 
accumulate in the lungs (79).  By postnatal day 5, adenosine levels start to 
increase, and by postnatal day 18 Ada-/- mice exhibit activated macrophages, 
airway epithelial thickening, and increased mucous production (119).  Adenosine 
concentrations found in the lungs of Ada-/- mice resemble the levels measured in 
patients of chronic lung disease (50).  In addition, Ada-/- mice display a multi 
organ pathology due to systemic elevations of adenosine and deoxyadenosine, 
which accumulates in the spleen and thymus leading to a severe combined 
immunodeficiency (62).  Moreover, the pulmonary phenotype in Ada-/- mice is 
characterized by a Th2 cytokine response  (62) that is associated with the 
upregulation of cytokines, chemokines, and mediators of airspace enlargement 
that promote pulmonary pathology (82).  This is similar to what is seen in patients 
with chronic lung disease.  Furthermore, the pathology observed in the lungs of 
Ada-/- mice correlates with histopathologic features observed in chronic lung 
disease (62).  These features include eosinophilia, mucus metaplasia, mast cell 
degranulation (as seen in asthma), neutrophilia, alveolar macrophage activation, 
distal air-space enlargement (as seen in COPD), and subepithelial and distal 
airway fibrosis (as seen in IPF) (64,65).  Additionally, Ada-/- mice treated with 
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ADA enzyme therapy from birth develop normally and do not exhibit increased 
levels of adenosine or chronic lung disease. Moreover, ADA enzyme therapy is 
able to reduce adenosine levels and reverse the features of pulmonary disease 
with the exemption of airspace enlargement (62).  Thus, adenosine signaling is 
able to directly cause lung pathology in this model making it useful for assessing 
the role of adenosine in chronic lung disease.   
 
GENETIC REMOVAL OF IL-6 IN ADA-DEFICIENT MICE 
Studies in Ada-/- mice demonstrate that IL-6 is elevated in conjunction with 
increased lung inflammation, mucus production, and fibrosis (82, 122).  
Preliminary data shows that IL-6 production remains unchanged in Ada-/- mice 
until adenosine levels begin to increase (Corrigan, unpublished data).  In 
addition, treatment of Ada-/- mice with a selective A2BR antagonist results in 
reduced pulmonary inflammation and decreased lung damage concurrently with 
reduced IL-6 production (79).  This demonstrates that IL-6 elevations in Ada-/- 
mice are mediated by adenosine in an A2BR-dependent manner.  Furthermore, 
IL-6 levels have been shown to be elevated in patients with chronic lung disease 
in correlation with disease severity and morbidity (113, 114).  Given the ability of 
IL-6 to perpetuate the chronic state of various inflammatory diseases (88-90), we 
hypothesized that elevations of IL-6 regulate features of chronic lung diseases in 
Ada-/- mice.  To determine the contribution of IL-6, Ada/IL-6 double knockout 
mice (Ada/IL-6-/-) were generated and their pulmonary phenotypes were analyzed 
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in comparison with Ada-/- mice.   These genetic studies serve to characterize the 
phenotypic changes in Ada-/- mice associated with IL-6. 
 
IL-6 NEUTRALIZATION IN ADA-DEFICIENT MICE 
The pulmonary phenotype observed in Ada-/- mice demonstrate its utility 
for examining the mechanisms by which adenosine regulates features of chronic 
lung disease.  In this model, adenosine regulates the pleiotropic cytokine IL-6, 
which has different effects on inflammation and fibrosis.  Genetic removal of IL-6 
in Ada-/- mice decreases pulmonary pathology.  This suggests that IL-6 regulates 
inflammation and fibrosis in this model.  As an additional mechanism to assess 
the role of IL-6 in the development of pulmonary phenotypes with the emphasis 
on pursuing therapeutic approaches, Ada-/- mice were treated systemically with 
IL-6 neutralizing antibodies.  This neutralization approach demonstrated 
therapeutic benefits in attenuating chronic pulmonary phenotypes in the Ada-/- 
mice.  Thus, neutralization of IL-6 in this model revealed that IL-6 signaling is 
involved in the initiation, maintenance and/or progression of chronic inflammation 
and fibrosis.  The significance of this study is highlighted by the fact that there is 
a lack of effective therapies that halt the progression of chronic lung diseases 
(132).    
 
SPECIFIC QUESTIONS AND EXPERIMENTAL RATIONALE 
Extensive studies have demonstrated that IL-6 is induced by adenosine in 
a variety of cells, such as peritoneal and alveolar macrophages, bronchial 
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smooth muscle cells, and human lung fibroblasts (133-135).  In Ada-/- mice, IL-6 
is elevated in conjunction with chronic pulmonary phenotypes.  Antagonism of 
the A2BR in this model leads to decreased IL-6 levels and diminished features of 
chronic lung disease.  Furthermore, this relationship between adenosine and IL-6 
is via the engagement of the A2BR (79). However, the source of IL-6 production 
and the cellular targets of IL-6 remain unknown.  Identification of the cells that 
express IL-6 and the cells that are targeted by IL-6 are both critical in 
understanding the signaling mechanisms by which IL-6 exerts its function in this 
model.  Thus, in this chapter I characterize IL-6 expression and its contribution 
via phospho-STAT-3 activation in the lung disease seen in Ada-/- mice in order to 
reveal potential signaling pathways that may be involved in human patients with 
chronic lung diseases.  This study provides a better understanding for the 
contribution of IL-6 in the lungs of Ada-/- mice and the involvement of IL-6 in 
chronic lung diseases.  
 
RESULTS 
IL-6 EXPRESSION AND STAT-3 ACTIVATION IN ADA-DEFICIENT MICE 
Elevated expression of IL-6 in the lungs of Ada-/- mice 
Increased levels of IL-6 in the lungs of Ada-/- mice have been proposed to 
be mediated by the A2BR (79).  To confirm IL-6 elevations during active disease 
in Ada-/- mice, quantitative RT-PCR whole-lung RNA extracts (Fig 3.1a) and IL-6 
protein measurements in bronchoalveolar lavage (46) fluid (Fig 3.1b) were 
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determined at a stage when adenosine levels and tissue pathology were 
increased (119).    Results demonstrated a 2.5 fold increase of IL-6 transcripts 
and a 1.7 fold increase of IL-6 protein in the BAL fluid of Ada-/- mice.  IL-6 levels 
in the lungs of Ada-/- mice were diminished following treatment with PEG-ADA to 
lower adenosine levels (Fig 3.1b).  To explore the source of IL-6 in this model, 
immunolocalization was performed on lung sections. Alveolar macrophages and 
bronchial airway epithelial cells were identified as the major cells producing IL-6 
in the lungs of Ada-/- mice (Fig 3.1c).  Interestingly, IL-6 immunoreactivity on 
these cells was reduced following PEG-ADA treatment.  These findings 
demonstrate that alveolar macrophages and bronchial airway epithelial cells 
produce IL-6 in an environment of elevated adenosine. 
 
Increased phospho-STAT-3 in the lungs of ADA-deficient mice. 
IL-6 binds to the IL-6 receptor to ultimately lead to the phosphorylation of 
STAT-3 and its translocation to the nucleus of cells in order to activate the 
transcription of target genes (90).  Thus, the use of phosphorylated antibodies 
against STAT-3 serves to indicate cellular targets of IL-6.  To examine IL-6 
cellular target activation, STAT-3 western blot analysis was performed on whole 
lung homogenates.  This analysis demonstrated increased phospho-STAT-3 
activation in Ada-/- mice compared to ADA-competent mice (Fig 3.2a).  Phospho-
STAT-3 levels were significantly diminished in the lungs of Ada-/- mice treated 
with PEG-ADA (Fig 3.2b).  To identify the potential IL-6 cellular targets in this 
model, immunohistochemical experiments were performed on lung sections to 
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determine phospho-STAT-3 localization.  In Ada-/- mice, nuclear phospho-STAT-
3 staining was observed on bronchial airway epithelial cells and predominantly 
on airway epithelial cells in the alveolar airspaces (Fig 3.2c).  The increased 
phosho-STAT-3 activation in these cells was reversed by treatment with PEG-
ADA (Fig 3.2c, upper and lower right panel).  These results suggest that 
phospho-STAT-3 activation on bronchial epithelial cells may be an indication of 
increased IL-6 signaling in these cells.  
 
Ada/IL-6 DOUBLE-KNOCKOUT MICE EXHIBIT DECREASED PULMONARY 
INFLAMMATION, FIBROSIS AND STAT-3 ACTIVATION. 
 
For the genetic studies, ADA/IL-6 double knockout (Ada/IL-6-/-) mice were 
generated by breeding Ada-/- mice with IL-6-/- mice.  Ada/IL-6-/- mice were treated 
with PEG-ADA since birth to avoid ADA deficiency lethality and to allow for 
normal development.  Enzyme therapy was halted at postnatal day 25 and 
pulmonary endpoints were analyzed at postnatal day 43 to compare Ada/IL-6-/- 
mice and Ada-/- mice and determine the contribution of IL-6 in this model (Fig 
3.3). 
 
PULMONARY PATHOLOGY IN Ada/IL-6 DOUBLE KNOCKOUT MICE 
In association with elevations in IL-6, the adenosine-mediated pulmonary 
injury in the Ada-/- mice is characterized by an increased influx of inflammatory 
cells  and  fibrosis  in  the  distal  airways.    Ada/IL-6-/-  mice  were  generated  to 
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Figure 3.1 
IL-6 expression in the lungs of ADA-deficient mice. 
IL-6 localization, protein expression, and transcript levels were assessed in lung 
sections, BAL fluid, and whole lungs from postnatal day 18-20 Ada+,  Ada-/- mice, 
and postnatal day 21 Ada-/- mice 72 hours after treatment with PEG-ADA.   
(a) IL-6 transcript levels were measured from whole-lung RNA extracts using 
quantitative RT-PCR with specific IL-6 primers.  Data presented as the 
percentage of β-actin ± SEM, n≥4.  (b) IL-6 protein levels were quantified from 
the BAL fluid using an ELISA kit.  Values are presented as pg/mg of protein ± 
SEM, n≥4. (*, p ≤ 0.001 Ada+ vs. Ada-/- and #, p ≤ 0.01 Ada-/- vs. Ada-/- + PEG-
ADA).   (c) Immunohistochemical localization of IL-6 expression, alveolar 
macrophages (black arrows), bronchial epithelial cells (red arrows).  Images are 
representative of 4 animals from each group.  Scale bars: 10 µm. 
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Figure 3.2 
Increased phosphorylated STAT-3 in the lungs of ADA-deficient mice. 
Phospho-STAT-3 localization and protein expression were assessed in lung 
sections from postnatal day 18 Ada+, Ada-/- mice, and postnatal day 21 Ada-/- 
mice 72 hours after treatment with PEG-ADA.  (a) Immunohistochemical 
localization of phospho-STAT-3 expression, alveolar epithelial cells (blue 
arrows), bronchial epithelial cells (red arrows).  Images are representative of 4 
animals from each group.  Scale bars: 100 µm. (b) Phospho-STAT-3 protein 
expression was measured from whole-lung extracts using western blot analysis 
with an antibody against phospho-STAT-3.  Total STAT-3 levels were also 
examined and α-actin levels were used as loading controls.  (c) Phospho-STAT-
3 band intensity was quantified using ImageJ analysis.  Values are presented as 
the percentage of α-actin ± SEM, n≥4. (*, p ≤ 0.05 Ada+ vs. Ada-/- and #, p ≤ 0.05 
Ada-/- vs. Ada-/- + PEG-ADA). 
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determine the contribution of IL-6 to the pulmonary phenotypes observed in Ada-/- 
mice.  Lung histopathology through examination of H&E sections from these 
mice demonstrated a reduction in pulmonary injury in Ada/IL-6-/- mice compared 
in parallel to Ada-/- mice (Fig 3.4).  Ada/IL-6-/- mice were characterized with 
decreased pulmonary inflammation, reduced airspace enlargement, and 
diminished fibrosis (Fig 3.4, bottom right panel).  This suggests that in the Ada-/- 
mice, in the setting of increased adenosine concentrations IL-6 contributes to the 
development of pulmonary pathology including pulmonary inflammation, airway 
destruction, and fibrosis. 
 
PULMONARY INFLAMMATION IN Ada/IL-6 DOUBLE KNOCKOUT MICE 
Ada/IL-6-/- mice exhibited decreased pulmonary inflammation compared 
Ada-/- mice.  BAL was performed on these mice and recovered inflammatory cells 
were counted using a hemocytometer.  Analysis of cellular differentials allowed 
identification of macrophages, neutrophils, and lymphocytes.  Quantification on 
the level of inflammation based from BAL analysis demonstrated a significant 
reduction in Ada/IL-6-/- mice of inflammatory cells, including macrophages, 
neutrophils,  and  lymphocytes  (Fig 3.5a-c)  compared  to  Ada-/- mice.  These 
results demonstrate that IL-6 is involved in the regulation of the inflammatory 
response observed in this model. 
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Figure 3.3 
Schematic Diagram of Methodology Employed in ADA-deficient Mice.   
To determine the role of IL-6 in Ada-/- mice two approaches were utilized.  The 
genetic studies consisted of generating ADA/IL-6 double knockout (Ada/IL-6-/-) 
mice by backcrossing Ada-/- mice and IL-6-/- mice.  To avoid ADA deficiency 
lethality, Ada/IL-6-/- mice were treated with PEG-ADA since birth until postnatal 
day 25 to allow for normal development.  Once ADA enzyme therapy was halted, 
pulmonary endpoints were analyzed at postnatal day 43 between Ada/IL-6-/- mice 
and Ada-/- mice.  The neutralization studies consisted of analyzing the therapeutic 
benefits of neutralizing IL-6 during the development of disease progression.  In 
this approach, Ada-/- mice were treated with PEG-ADA from birth until postnatal 
day 25 for normal development, followed by treatments of an IL-6 antibody or an 
isotype control antibody.  At postnatal day 43, pulmonary endpoints were 
analyzed to characterize the effectiveness of neutralizing IL-6.     
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Figure 3.4  
Pulmonary phenotypes following genetic removal of IL-6 in ADA-deficient 
mice.  
 
Histology of the lungs from postnatal day 43 Ada+, Ada-/-, and Ada/IL-6-/- mice. 
Examination of lung histology through H&E staining revealed that Ada/IL-6-/- mice 
displayed a reduction in lung inflammation, airway enlargement, and fibrosis. 
Images are representative of 8 animals from each group. Scale bars: 200 µm.  
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Figure 3.5  
Pulmonary inflammation following genetic removal of IL-6 in ADA-deficient 
mice.  
 
 (a) Total cell numbers in BAL fluid were counted using a hemocytometer. BAL 
cells were cytospun and stained with Diff-Quick, allowing for quantification of 
macrophages (b) and lymphocytes, eosinophils, and neutrophils (c). Data are 
presented as mean cell counts ± SEM, n≥8. (*, p ≤ 0.05 Ada+ vs. Ada-/- and #, p ≤ 
0.05 Ada-/- vs. Ada/IL-6-/-). 
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PULMONARY FIBROSIS IN Ada/IL-6 DOUBLE KNOCKOUT MICE  
In addition, Ada-/- mice develop features of pulmonary fibrosis in particular 
collagen production and deposition (119).  To determine the role of IL-6 on 
fibrosis in this model, Ada/IL-6-/- mice were analyzed for fibrotic assessment.  In 
this study, examination of metrics of pulmonary fibrosis revealed that Ada/IL-6-/- 
mice displayed reduced levels of collagen production (Fig 3.6a) and diminished 
myofibroblast accumulation α-SMA (Fig 3.6b).  This was supported by 
morphologic Ashcroft scores (Fig 3.6c).  These results demonstrate that the 
removal of IL-6 is associated with diminished pulmonary fibrosis.  Thus, this 
suggests that in the Ada-/- mice IL-6 is displaying a pro-fibrotic role by regulating 
key features of pulmonary fibrosis including collagen production and 
myofibroblast accumulation.   
 
ALVEOLAR DESTRUCTION IN Ada/IL-6 DOUBLE KNOCKOUT MICE 
Alveolar airspace enlargement is another feature of Ada-/- mice that is a 
characteristic of emphysema and COPD.  Ada/IL-6-/- mice were analyzed to 
determine whether IL-6 was involved in the regulation of airspace enlargement.  
The size of alveolar airspace was also diminished by the genetic removal of IL-6 
(Fig 3.7a-b) in comparison with Ada-/- mice.  This indicates that in the absence of 
IL-6 there is reduced alveolar destruction in the lungs of Ada-/- mice.    
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Figure 3.6 
Pulmonary fibrosis following genetic removal of IL-6 in ADA-deficient mice.  
 
Collagen production. (a) Soluble collagen levels were measured using the Sircol 
Assay. Data are presented as mean µg collagen/ml BAL. Data are presented as 
mean cell counts ± SEM, n≥8. (*, p ≤ 0.05 Ada+ vs. Ada-/- and #, p ≤ 0.05 Ada-/- 
vs. Ada/IL-6-/-).  (b) Lung sections were stained with an antibody against for α-
SMA to visualize myofibroblast accumulation (pink stain).  Images are 
representative of 6 animals from each group.  Scale bars: 100 µm. (c) Ashcroft 
scores were used to determine the degree of fibrosis (*, p ≤ 0.05 Ada+ vs. Ada-/- 
and #, p ≤ 0.05 Ada-/- vs. Ada/IL-6 -/-, n≥6).   
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Figure 3.7  
Alveolar destruction following genetic removal of IL-6 in ADA-deficient 
mice.  
 
(a) Histology of the lungs from postnatal day 43 Ada+, Ada-/-, and Ada/IL-6-/- mice 
revealing diminished alveolar airspace destruction. Images are representative of 
8 animals from each group.  Scale bars: 200 µm.  (b) Quantitative analysis of 
alveolar airspace size calculated using Image-Pro analysis software.  Values are 
presented as mean chord lengths in µm ± SEM, n≥8. (*, p ≤ 0.05 Ada+ vs. Ada-/- 
and #, p ≤ 0.05 Ada-/- vs. Ada/IL-6-/-). 
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STAT-3 ACTIVATION IN EPITHELIAL CELLS IN ADA-DEFICIENT MICE 
FOLLOWING GENETIC REMOVAL OF IL-6 
STAT-3 is a well known target of IL-6 (90).  Examination of the status of 
STAT-3 activation reveals that Ada-/- mice display an enhanced phosphorylation 
of STAT-3.  However, Ada/IL-6-/- mice exhibit reduced STAT-3 activation (Fig 
3.8a-b). Immunolocalization of phospho-STAT-3 revealed a reduction of nuclear 
staining in alveolar epithelial cells of Ada/IL-6-/- mice (Fig. 3.8c). These results 
suggest that in the Ada-/- mice, IL-6 promotes STAT-3 activation in airway 
epithelial cells and contributes to pulmonary inflammation, airspace destruction 
and fibrosis. 
 
IL-6 NEUTRALIZATION IN ADA-DEFICIENT MICE IS ASSOCIATED WITH 
DECREASED PULMONARY INFLAMMATION, FIBROSIS, AND STAT-3 
ACTIVATION. 
 
PULMONARY PATHOLOGY IN ADA-DEFICIENT MICE FOLLOWING IL-6 
NEUTRALIZATION 
 
Results in Ada/IL-6-/- mice suggest that IL-6 targeted therapies may be 
useful in the treatment of adenosine-mediated pulmonary inflammation and 
fibrosis.  To assess this further, Ada-/- mice were treated systemically with an IL-6 
neutralizing antibody (Fig 3.3).  Treatment of Ada-/- mice with the IL-6 neutralizing 
antibodies was performed via subcutaneous injections at postnatal day 26, 31, 
and 37.  The exposure levels of the anti-IL-6 antibody were determined by ELISA 
in the plasma and BAL fluid (Fig 3.10).  No significant difference was observed 
on the plasma levels between the Ada+ mice and Ada-/- mice (~300 µg/ml), 
suggesting consistent exposure.   Whereas in the lung, anti-IL-6 exposure levels  
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Figure 3.8  
STAT-3 activation following genetic removal of IL-6 in ADA-deficient mice.  
 (a) Phospho STAT-3 activation.  Western Blot analysis was performed using an 
antibody against phospho-STAT-3 in whole lungs lysate from postnatal day 43 
Ada+ and Ada/IL-6-/- mice.  STAT-3 andα-actin were used as controls.  (b) 
Phospho-STAT-3 band intensity was quantified using ImageJ analysis.  Values 
are presented as the percentage of α-actin ± SEM, n≥4. (*, p ≤ 0.05 Ada+ vs. 
Ada-/- and #, p ≤ 0.05 Ada-/- vs. Ada/IL-6 -/-).  (c) Immunolocalization of phospho-
STAT-3 expression. Lung sections were stained with an antibody specific for 
phospho-STAT-3 on alveolar epithelial cells (blue arrows). Images are 
representative of 8 animals from each group.  Scale bars: 100 µm. 
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in the BAL fluid  were  significantly  different between the Ada+ mice (0.23 µg/ml) 
and Ada-/- mice (1.93 µg/ml).  This may be due to the increased vascular barrier 
disruption observed in the Ada-/- mice.  Nonetheless, the similar levels in the 
plasma from Ada+ and Ada-/- mice suggest that adequate anti-IL-6 exposure is 
achieved.  Examination of lung histology through H&E staining revealed that Ada-
/-
 mice treated with the isotype antibody developed severe inflammation and 
damage. Conversely, Ada-/- mice treated with the anti-IL-6 antibody displayed a 
reduction in lung inflammation, air-space enlargement, and fibrosis (Fig 3.9).  
These findings suggest that IL-6 contributes to the development and progression 
of pulmonary inflammation and fibrosis in the Ada-/- mice and that IL-6 based 
therapeutic approach may provide benefits in adenosine-driven lung disease. 
 
PULMONARY INFLAMMATION IN ADA-DEFICIENT MICE FOLLOWING IL-6 
NEUTRALIZATION 
 
To quantify the reduced pulmonary inflammation observed on histologic 
findings, BAL was performed and recovered inflammatory cells were counted 
using a hemocytometer.  Results revealed characteristic increases in total 
inflammatory cells recovered from BAL fluid of Ada-/- mice versus Ada+ mice, but 
a significant reduction was observed in Ada-/- mice treated with IL-6 neutralizing 
antibodies (Fig 3.11a).  Analysis of BAL cellular differentials revealed that IL-6 
neutralization led to a significant reduction in all cell types examined including 
macrophages (Fig 3.11b), lymphocytes, eosinophils, and neutrophils (Fig 3.11c).  
These data suggest that IL-6 contributes to pulmonary inflammation in Ada-/- 
mice. 
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Figure 3.9  
Pulmonary phenotypes following neutralization of IL-6 in ADA-deficient 
mice.  
 
Lungs from postnatal day 43 Ada+  mice treated with the isotype antibody (upper 
left) or IL-6 antibody (upper right) and Ada-/- mice treated with the isotype 
antibody (lower left) or IL-6 antibody (lower right) were infused with fixative under 
constant pressure (25cm H20) and processed for H&E staining.  Assessment of 
lung inflammation and damage in Ada-/- mice following subcutaneous injections 
with an anti IL-6 antibody (30 mg/kg) displayed a reduction in lung inflammation, 
airway enlargement, and fibrosis.  Images are representative of 11 animals from 
each group. Scale bars: 200 µm.  
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Figure 3.10  
Anti IL-6 exposure in ADA-deficient mice.  
 
PK analysis revealing the IL-6 antibody exposure levels in the plasma and BAL.  
Data are presented as mean µg/ml IL-6 antibody ± SEM, n≥11.   (*** p <0.001 
using one way ANOVA and Bonferonnis Multiple comparison test).   
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Figure 3.11  
Pulmonary inflammation following neutralization of IL-6 in ADA-deficient 
mice.  
 
Bronchoalveolar lavage (46) was performed on postnatal day 43 Ada+ or Ada-/- 
mice treated with the isotype or IL-6 antibody.  (a) Total cells numbers in lavage 
fluid were counted using a hemocytometer.   BAL cells were cytospun and 
stained with Diff-Quick, allowing for determination of macrophages (b) and 
lymphocytes, eosinophils, and neutrophils (c).  Data are presented as mean cell 
counts ± SEM, n≥11. (*, p ≤ 0.05 Ada+ vs. Ada-/- and #, p ≤ 0.05 Ada-/- vs. Ada-/- + 
IL-6 Antibody). 
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PULMONARY FIBROSIS IN ADA-DEFICIENT MICE FOLLOWING IL-6 
NEUTRALIZATION 
 
In conjunction with increases in tissue levels of adenosine, Ada-/- mice 
develop features of pulmonary fibrosis including the production and deposition of 
collagen (79, 119, 136).  We next sought to determine if treatment with IL-6 
neutralizing antibodies had a therapeutic effect on the pulmonary fibrosis seen in 
Ada-/- mice.  Collagen production and deposition were examined to determine the 
effect of IL-6 neutralization on pulmonary fibrosis in this model.  Treatment of 
Ada-/- mice with IL-6 neutralizing antibodies resulted in reduced soluble collagen 
levels in BAL fluid (Fig 3.12a).  Furthermore, examination of α1-procollagen 
transcript levels (Fig 3.12b) and airway collagen deposition (Fig 3.13b) revealed 
enhanced collagen production in the lungs of Ada-/- mice that were attenuated 
following anti-IL-6 treatment.  Staining for α-SMA revealed prominent 
myofibroblast accumulation in the distal airways of Ada-/- mice (Fig 3.12c).  This 
accumulation was largely prevented in Ada-/- mice following IL-6 neutralization.  
Thus, in anti-IL-6-treated Ada-/- mice, pulmonary fibrosis was attenuated as 
indicated by the reduction of key fibrotic indexes including Ashcroft scores (Fig 
3.12d).  In addition, the production of fibronectin, an extracellular matrix protein 
involved in inflammation, airspace destruction, and pulmonary fibrosis (39), was 
examined in Ada-/- mice treated with isotype or IL-6 neutralizing antibodies.  Ada-
/-
 mice exhibited an increase in fibronectin production and deposition that was 
diminished by IL-6 neutralization (Fig 3.13a, c).  Collectively, these findings 
indicate that in Ada-/- mice, IL-6 signaling is involved in regulating the production  
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Figure 3.12  
Pulmonary fibrosis following neutralization of IL-6 in ADA-deficient mice.  
 
Fibrotic characteristics were assessed from lung sections from postnatal day 43 
Ada+ mice treated with the isotype antibody, Ada-/- mice treated with the isotype 
antibody or Ada-/- mice treated with the IL-6 antibody.  (a) Decreased collagen 
levels.  Soluble collagen protein levels were measured using Sircol Assay.  Data 
presented as mean µg collagen/ml BAL fluid ± SEM, n≥8. (*, p ≤ 0.05 Ada+ vs. 
Ada-/- and #, p ≤ 0.05 Ada-/- vs. Ada-/- + IL-6 Antibody). (b) Decreased collagen 
production.  Whole-lung α1-procollagen transcript levels measured using 
quantitative RT-PCR.  Data are presented as mean normalized 18S rRNA 
transcript levels (∆-ct) ± SEM, n≥4. (*, p ≤ 0.05 Ada+ vs. Ada-/- and #, p ≤ 0.05 
Ada-/- vs. Ada-/- + IL-6 Antibody).  (c) Decreased myofibroblast accumulation.  
Lung sections were stained with an antibody against for α-SMA to visualize 
myofibroblast (pink stain).  Images are representative of 6 animals from each 
group.  Scale bars: 100 µm.  (d) Ashcroft scores were used to determine the 
degree of fibrosis (*, p ≤ 0.05 Ada+ vs. Ada-/- and #, p ≤ 0.05 Ada-/- vs. Ada-/- + IL-
6 Antibody, n≥6). 
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Figure 3.12  
IL-6 neutralization in ADA-deficient mice is associated with decreased 
pulmonary fibrosis.  
 
(a) Decreased fibronectin production.  Whole-lung fibronectin transcript levels 
measured using RT-PCR.  Data presented as mean normalized 18S rRNA 
transcript levels (∆-ct) ± SEM, n≥4. (*, p ≤ 0.05 Ada+ vs. Ada-/- and #, p ≤ 0.05 
Ada-/- vs. Ada-/- + IL-6 Antibody).  (b)  Decreased collagen deposition.  Lung 
sections were stained with Masson’s Trichome to visualize collagen deposition 
(blue stain).   (c) Decreased fibronectin deposition.  Lung sections were treated 
with a specific fibronectin antibody (red stain).  Images are representative of 8 
animals from each group.  Scale bars: 200 µm.   
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and deposition of collagen and fibronectin and in the regulation of myofibroblasts 
accumulation, common features seen in the progression of pulmonary fibrosis. 
 
 
INFLAMMATORY MEDIATORS IN ADA-DEFICIENT MICE FOLLOWING IL-6 
NEUTRALIZATION 
 
To examine potential mechanisms by which IL-6 neutralization causes 
diminished pulmonary inflammation in Ada-/- mice, cytokine and chemokine 
transcript levels were measured in whole lung RNA extracts.  Results 
demonstrated characteristic increases of proinflammatory cytokine expression in 
the lungs of Ada-/- mice, but a significant reduction was observed in cytokines 
and chemokines known to be IL-6 target (Fig 3.13).   Among the proinflammatory 
cytokines and chemokines found to be reduced via IL-6 neutralization were 
CXCL1, CCL2 (MCP-1), osteopontin (OPN), IL-17, and CXCL-2 (MIP-2).  In 
contrast, expression of TNF-α and TGF-β (data not shown) were found to be 
elevated in the lungs of Ada-/- mice treated with isotype antibodies; however, their 
expression was not reduced following IL-6 neutralization.  These findings suggest 
that IL-6 significantly influences the expression of certain proinflammatory 
cytokines and chemokines, which are known mediators that contribute to the 
pulmonary inflammation observed in the lungs of Ada-/- mice. 
 
MEDIATORS OF ALVEOLAR DESTRUCTION IN ADA-DEFICIENT MICE 
FOLLOWING IL-6 NEUTRALIZATION 
 
ADA-deficient display features of alveolar airspace enlargement 
resembling emphysema (79).  To determine the effects of IL-6 neutralization on  
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Figure 3.13  
Proinflammatory mediators in mice treated with IL-6 neutralizing 
antibodies.  
Transcript levels of various proinflammatory cytokines and chemokines were 
measured in whole-lung RNA extracts from postnatal day 43 mice using 
quantitative RT-PCR.  Shown are levels of (a) CXCL-1, (b) CCL2 [MCP-1], (c) 
Osteopontin [OPN], (d) IL-17, (e) CXCL2 [MIP-2], and (f) TNF-α. Transcripts 
were measured in parallel with 18S rRNA and values are presented as mean 
normalized transcript levels (∆-ct) ± SEM, n≥4. (*, p ≤ 0.05 Ada+ vs. Ada-/- and #, p 
≤ 0.05 Ada-/- vs. Ada-/- + IL-6 Antibody). 
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this phenotype, mean chord length analysis was conducted on lungs from Ada-/- 
mice treated with IL-6 neutralizing antibodies.  Results demonstrated that the 
enlarged airspaces observed in the Ada-/- mice were prevented with treatment 
with anti-IL-6 antibodies (Fig 3.14a, b).  These data demonstrate that alveolar 
destruction in the lungs of Ada-/- mice can be prevented via IL-6 neutralization. 
Alveolar airspace enlargement is characterized by a disruption in the 
balance between the levels of MMPs and inhibitors of proteases (79).  Ada-/- mice 
exhibits increased expression of tissue inhibitor of metalloproteinase-1 (TIMP-1), 
MMP-9, and MMP-12 (79).  Examination of these mediators in the lungs of Ada-/- 
mice treated with IL-6 neutralizing antibodies revealed diminished expression of 
TIMP-1 and MMP-9, while MMP-12 levels remained elevated (Fig 3.15a-d).  
MMP-9 immunostaining confirmed increased MMP-9 protein levels in 
inflammatory cells in the lungs of Ada-/- mice, and significant reductions following 
IL-6 neutralization (Fig 3.15e).  These results suggest that IL-6 signaling is 
involved in the regulation of alveolar airspace destruction by the regulation of 
these key regulators. 
 
 
VASCULAR PERMEABILITY IN ADA-DEFICIENT MICE FOLLOWING IL-6 
NEUTRALIZATION 
 
Previous studies indicate that A2BR signaling preserves endothelial barrier 
function during hypoxia and lung injury (129, 137), and A2BR deficiency enhances 
vascular leakage in Ada-/- mice .  In the setting of elevated adenosine levels, 
A2BR regulates cytokine production including IL-6 (79).  Furthermore, excess IL-6 
produces  gastrointestinal  barrier  dysfunction by downregulating tight junction  
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Figure 3.14  
Alveolar destruction following neutralization of IL-6 in ADA-deficient mice.  
 
(a) Histological examination of H&E lung sections from postnatal day 43 Ada+ 
mice treated with the isotype antibody or IL-6 antibody and Ada-/- mice treated 
with isotype antibody or IL-6 antibody (lower right). Images are representative of 
11 animals from each group.  Scale bars: 200 µm.  (b) Quantitative analysis of 
alveolar airspace size calculated using Image-Pro analysis software.  Values are 
presented as mean chord lengths in µm ± SEM, n≥11. (*, p ≤ 0.05 Ada+ vs. Ada-/- 
and #, p ≤ 0.05 Ada-/- vs. Ada-/- + IL-6 Antibody).  
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Figure 3.15  
Alveolar destruction mediators in mice treated with IL-6 neutralizing 
antibodies.  Transcript levels of TIMP-1 (a), MMP-9 (c), and MMP-12 (d) 
measured from whole-lung RNA extracts using RT-PCR.  Transcripts were 
measured in parallel with 18S rRNA and values are presented as mean 
normalized transcript levels (∆-ct) ± SEM, n≥4. (b) TIMP-1 protein levels were 
measured in BAL fluid using an ELISA kit.  Values are presented as ng/ml ± 
SEM, n≥6. (*, p ≤ 0.05 Ada+ vs. Ada-/- and #, p ≤ 0.05 Ada-/- vs. Ada-/- + IL-6 
Antibody).  (e) MMP-9 immunolocalization in Ada-/- mice.  Images are 
representative of 8 animals from each group.  Scale bars: 200 µm. 
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protein metabolism (138).  Hence, to address the role of IL-6 on endothelial 
barrier function, Ada-/- mice treated with an anti-IL-6 antibody or isotype antibody 
were subjected to comparative analysis of vascular permeability as assessed by 
Evans blue dye extravasation.  Results indicated a significant increase in 
vascular leakage in lungs of Ada-/- mice.  This increase was prevented by the 
treatment of Ada-/- mice with IL-6 neutralizing antibodies (Fig 3.16 a, b).  Hence, 
neutralization of IL-6 is associated with restored vascular permeability in Ada-/- 
mice.  These findings indicate that IL-6 serves as an important mediator for 
pulmonary endothelial barrier function in Ada-/- mice.   
 
MUCUS CELL METAPLASIA IN ADA-DEFICIENT MICE FOLLOWING IL-6 
NEUTRALIZATION 
 
Elevations of adenosine in the airways of Ada-/- mice are observed in 
conjunction with prominent features of mucous cell metaplasia in the bronchial 
airways (79).  To determine the necessity of IL-6 in mucin production in this 
setting of increased adenosine levels, Ada-/- mice were treated with an IL-6 
antibody to assess the impact on mucus metaplasia.  Ada-/- mice displaying 
pulmonary phenotypes at postnatal day 18 were subjected to treatment of anti-IL-
6 or Isotype antibody and were sacrificed at postnatal day 21 to assess mucin 
production (Fig 3.17a).  Tissue sections from these mice were stained with PAS, 
and morphometry using Image-Pro allowed for quantification of mucous cell 
metaplasia.  As previously reported, Ada-/- mice displayed an increase in mucin-
producing cells in the bronchial airways (119) (Fig 3.17b, middle panel).  
However,   treatment   with   anti-IL-6  antibody   led   to  the  reduction  of  mucin  
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Figure 3.16  
Vascular permeability following neutralization of IL-6 in ADA-deficient mice.  
 
Vascular permeability analysis in Ada-/- and Ada+ mice were treated with an IL-6 
neutralizing antibody.  At postnatal day 43, mice were subjected to intraperitoneal 
injections with Evans Blue Dye and the heart and lungs were collected 4 hrs after 
injection.  (a) Representative images of lungs.  (b) Evans blue dye 
concentrations were quantified in the heart and lungs.  Data are presented as 
mean dye content in micrograms per gram of lung tissue ± SEM, n≥4. (*, p ≤ 0.05 
Ada+ vs. Ada-/- and #, p ≤ 0.05 Ada-/- vs. Ada-/- + IL-6 Antibody). 
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production in the bronchial airways of Ada-/- mice (Fig 3.17b).  Quantification of 
the PAS-positive staining revealed significant differences in mucus levels 
following IL-6 neutralization in comparison isotype control antibody (Fig 3.17c)  
Real-time PCR was used to quantify the RNA transcripts of major mucin genes 
responsible for mucus metaplasia, such as Muc5ac, Muc5ab, and the mucous 
metaplasia marker calcium-activated chloride channel 3 (CLCA-3).  Although no 
significant differences were observed in Muc5ac and Muc5ab (data not shown), 
anti-IL-6 treated Ada-/- mice revealed a significant reduction in CLCA-3 (Fig 
3.17d).  This suggests that IL-6 regulates mucin secretion in the Ada-/- mice.  
 
 
STAT-3 ACTIVATION IN EPITHELIAL CELLS IN ADA-DEFICIENT MICE 
FOLLOWING NEUTRALIZATION OF IL-6 
 
STAT-3 is known to be the major effector of IL-6.  To examine the 
contribution of IL-6 in STAT-3 activation in Ada-/- mice, western blot analysis was 
performed.  Results revealed that Ada-/- mice exhibit increased levels of 
phospho-STAT-3, consistent with previous observations (Fig 3.3); however, Ada-
/-
 mice treated with IL-6 neutralizing antibodies demonstrated a substantial 
reduction of phospho-STAT-3 activation (Fig 3.18a, c).  As a confirmation of 
potential IL-6 cellular targets, phospho-STAT-3 immunolocalization revealed 
nuclear phospho-STAT-3 positive staining on bronchial airway epithelial cells and 
alveolar airway epithelial cells in isotype treated Ada-/- mice.  However, the 
observed increased phospho-STAT-3 nuclear staining was prevented in anti-IL-6 
treated Ada-/- mice (Fig 3.18c, right panel).  These results indicate that the  
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Figure 3.17  
Mucus Production following neutralization of IL-6 in ADA-deficient mice.  
 
Mucus production in Ada-/- mice treated with the anti-IL-6 antibody.  Lung 
sections from postnatal day 21 mice were stained with PAS to detect mucus 
deposition (pink stain).  (a) Schematic diagram illustrating experimental design of 
a single dose of anti-IL-6 via subcutaneous injection (30mg/kg) at postnatal day 
18, where pathological symptoms (lung inflammation and airway enlargement) 
are displayed.  (b) Examination of mucus production revealed a reduction of 
bronchial airways in the lungs of Ada-/- mice treated with the IL-6 neutralizing 
antibody.  (c) Mean mucus index showing the extent of mucus production 
determined by quantifying the amount of PAS-stained material using Image-Pro 
analysis. (d) Transcript levels of CLCA-3 were measured in whole-lung RNA 
extracts from postnatal day 21mice using quantitative RT-PCR.  Transcripts were 
measured in parallel with 18S rRNA and values are presented as mean 
normalized transcript levels (∆-ct) ± ± SEM, n≥4. (*, p ≤ 0.05 Ada+ vs. Ada-/- and #, 
p ≤ 0.05 Ada-/- vs. Ada-/- + IL-6 Antibody). 
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Figure 3.18  
STAT-3 activation following genetic removal of IL-6 in ADA-deficient mice.  
Phospho-STAT-3 expression assessed using western blot analysis (a), ImageJ 
analysis (b), and immunohistochemistry (c). STAT-3 and α-actin were used as 
loading controls.  Values are presented as the percentage of α-actin ± SEM, n≥4. 
(*, p ≤ 0.05 Ada+ vs. Ada-/- and #, p ≤ 0.05 Ada-/- vs. Ada-/- + IL-6 Antibody).  Lung 
sections were stained with an antibody specific for phospho-STAT-3, alveolar 
epithelial cells (blue arrows), bronchial epithelial cells (red arrows).  Images are 
representative of 8 animals from each group.  Scale bars: 100 µm.   
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increased levels of phospho-STAT-3 activation displayed in the Ada-/- mice can 
be prevented by neutralizing IL-6.   Thus, these observations suggest that IL-6 is 
the main activator of phospho-STAT-3 in the lungs of Ada-/- mice, and that 
blocking IL-6 mediated activation of STAT-3 may be an effective therapy for the 
treatment of pulmonary fibrosis. 
 
DISCUSSION 
Adenosine is a potent extracellular signaling molecule produced by 
various cells during normal metabolism (41) or as a result of cellular stress and 
damage (57-60).  Adenosine is able to activate either anti-inflammatory (tissue 
protective) or pro-inflammatory (tissue destructive) pathways (62-64, 67) 
depending on the type and duration of injury, the amount of adenosine produced, 
and the alteration in the expression of adenosine receptors.  Ada-/- mice display 
effects of chronic adenosine elevations, such as inflammation, alveolar air-space 
destruction, mucus metaplasia, and fibrosis (63).  Pharmacological studies 
demonstrated that the A2BR regulates the expression of key cytokines, 
chemokines, and proteases in conjunction with the adenosine-dependent 
phenotypes.  In particular, inhibition of the A2BR led to reduction in IL-6 
production (79) implicating a role for this profibrotic cytokine in the pathological 
conditions of inflammation and fibrosis in this model.  To confirm a role of IL-6 in 
the development of pulmonary phenotype, genetic studies involving Ada/IL-6-/- 
mice were analyzed.  In addition, Ada-/- mice were treated systemically with IL-6 
neutralizing antibodies. Thus, the role of IL-6 in this adenosine-mediated 
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pulmonary injury model was determined via complementary or confirmatory 
assays through neutralization and genetic studies.  
Our results demonstrated that genetic removal of IL-6 in Ada-/- mice led to 
reduced features of chronic lung disease, including inflammation, airspace 
enlargement, and fibrosis.  Furthermore, the neutralization of IL-6 corroborated 
these observations suggesting blocking IL-6 signaling may have clinical 
significance.  To pursue the mechanism by which IL-6 contributes to these 
fibrotic features, analysis of phospho-STAT-3 expression displayed elevations in 
this pathological condition.  This implies that IL-6 is signaling through STAT-3 
activation as a mechanism of action to contribute to the development and 
progression of pulmonary inflammation and fibrosis.   
My results also indicated a significant decrease in airway inflammation in 
Ada-/- mice after the genetic removal of IL-6 or the administration of IL-6 
neutralizing antibodies, with significant reduction of macrophages, neutrophils, 
lymphocytes, and eosinophils.  These findings confirm that IL-6 serves as an 
important mediator for pulmonary inflammation in models of chronic lung 
disease.   Neutralization of IL-6 in Ada-/- mice led to significant reduction of MCP-
1 and MIP-2 could account for the decreased macrophage recruitment, whereas 
reduction in OPN and CXCL-1 could account for the decreased neutrophilic 
infiltration.  Previous reports demonstrate that activation of STAT-3 by IL-6 
regulates neutrophil trafficking in acute inflammation (139).  Influx of neutrophils 
by OPN has been associated with air-space enlargement and remodeling via 
regulation of MMPs (140).  In addition, neutrophil accumulation leads to shedding 
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of sIL-6R promoting IL-6 trans-signaling events.  These events consist of 
decreasing CXCL1, CXCL8, and Fructalkine (141); conversely driving the 
expression of CXCL5 (ENA-78), CXCL6 (GCP2), and MCP-1 (141).  This 
immunological shift leads to neutrophil clearance and macrophage accumulation.  
Thus IL-6 trans-signaling is thought to be responsible for the transition from acute 
to chronic inflammation (142).  Regarding the role of IL-6 in macrophages, IL-6 is 
able to promote differentiation-inducing signals when STAT-3 is suppressed 
leading to M1 macrophage differentiation, whereas M2 macrophage polarization 
occurs upon STAT-3 activation (143).  This M2 lineage influences Th2-mediated 
responses and produces mediators that contribute to disease progression and 
fibrosis (144).  Thus, this study demonstrates that during chronic pulmonary 
phenotypes, Ada-/- mice exhibit increased activation of STAT-3, which is involved 
in M2 differentiation and successively in Th-2 mediated responses.  Hence, 
neutralizing IL-6 in this model leads to halted STAT-3 activation; this could 
consequentially lead decreased M2 differentiation and diminished Th2 
responses.  Furthermore, our results indicate that neutralization of IL-6 in Ada-/- 
mice results in reduced expression of OPN, CXCL-1, MCP-1, and MIP-2 (Fig 
3.13) thereby resulting in decreased neutrophil and macrophage infiltration, and 
preventing the production of mediators that contribute to the chronic state of this 
model.  
 Regarding lymphocytes, STAT-3 activation via IL-6 trans-signaling directs 
T cell migration in acute inflammation by up-regulating expression of CCL4 (MIP-
1β) and CCL5 (Rantes).  IL-6 mediated events in T cells include polarization, 
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adhesion, and anti-apoptotic effects contributing to the development of chronic 
inflammation (145).  My findings underline the complex role of IL-6 in 
inflammation, namely that IL-6 is involved in neutrophil mobilization and 
activation (141), while at the same time is able to regulate the transition from 
acute to chronic inflammation by increasing the mononuclear-cell infiltrate and 
favoring the neutrophilic infiltrate clearance (142).  Thus, it is conceivable that an 
imbalance in this transition from innate to acquired immunity leads to a distorted 
immunological regulation that results in disease progression.  The factors that 
govern this inappropriate regulation remain unclear.   
Additionally, IL-17 was another important cytokine that I found to be 
reduced by IL-6 neutralization.  IL-17-producing T helper cells (Th17 cells) are 
functionally important in host defense and its aberrant regulation is involved in 
the pathogenesis of multiple inflammatory and autoimmune disorders (102).  The 
differentiation of Th17 cells is controlled by TGF-β and IL-6, which initiates the 
lineage commitment by inhibiting Foxp3 and activating the transcription factors 
STAT-3 and RORγt (146).  While IL-6 is important for the generation of Th17 
cells, IL-23 is important for their maintenance, expansion, and survival.  IL-6-
deficient mice do not develop Th17 differentiation, but TGF-β and IL-21 are able 
to activate an alternative pathway to induce Th17 cells in the absence of IL-6 
(147).  In Ada-/- mice, IL-17 is upregulated suggesting that ADA deficiency is 
associated with Th17 autoimmunity.  However, Ada-/- mice treated with IL-6 
neutralizing antibodies had decreased IL-17 mRNA levels (Fig 3.13d).  
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Downregulation of IL-17 via neutralization of IL-6 suggests that the pathogenic 
Th17 cells can be prevented by inhibiting the initial lineage commitment. 
In addition to reduced inflammation, IL-6 neutralization in Ada-/- mice led to 
decreased alveolar destruction.  Analysis of important alveolar destruction 
mediators after IL-6 neutralization revealed that IL-6 is involved in the regulation 
of proteases and anti-proteases, such as MMP-9 and TIMP-1 (Fig 3.15).  The 
regulation of matrix metalloproteases by IL-6 has been reported previously (148).  
Furthermore, IL-6 is able to induce TIMP-1 expression in synovial fibroblasts via 
trans-signaling (149).  This suggests that IL-6 exerts its contribution to alveolar 
destruction in this model via the regulation of the expression of important 
cytokines, chemokines, and proteases.   
IL-6 neutralization in Ada-/- mice also resulted in rescued pulmonary 
vascular permeability (Fig 3.16).  In addition to the role of IL-6 mediating the 
inflammatory response, this preservation in vascular permeability may account in 
part for the decreased inflammatory cells (Fig 3.11).  In hypoxia-associated 
vascular leakage, genetic removal or pharmacological blockage of the A2BR has 
been shown to disrupt vascular permeability (150).  Furthermore, Ada-/- mice 
show enhanced pulmonary vascular leakage, which is further enhanced in 
ADA/A2BR double knock out mice (129).  This could be explained by the A2BR-
induced activation of PKA, which phosphorylates vasodilator-stimulated 
phosphoprotein (VASP) leading to barrier function disruption (151).  Hence, both 
models of hypoxia and ADA deficiency demonstrate that adenosine signaling 
regulates pulmonary vascular permeability.  Moreover, IL-6 is able to contribute 
77 
 
to gastrointestinal vascular leakage via downregulation of tight junction proteins, 
such as ZO-1 (138).  Hence, IL-6 neutralization may preserve pulmonary 
vasculature in Ada-/- mice by preventing downregulation of tight junction protein 
metabolism. 
Another prominent feature of Ada-/- mice is increased mucus production.  
In chronic inflammatory diseases, such as asthma, mucus production from lung 
epithelium leads to obstruction of the airways culminating in increased airflow 
resistance (79, 119).  Homeostatic mechanisms regulates mucus production and 
airway clearance in order to maintain proper lung function (152). Perturbation of 
these mechanisms leads to mucus hypersecretion and eventually lung 
dysfunction.  In response to fungal allergens, it has been shown that IL-6 is 
necessary for mucin overproduction (153).  It has been suggested that IL-6 
modulates mucus production as a consequence of regulating IL-13 expression 
(153).  In human lung epithelial cell lines, IL-6 is able to upregulate the mucin 
genes Muc5ac and Muc5b (154).  Although Muc5ac and Muc5b levels are 
increased in Ada-/- mice, no significant changes were observed following IL-6 
neutralization.  However, downregulation of CLCA-3 was observed in anti-IL-6 
treated Ada-/- mice (Fig 3.17d).  This suggests that IL-6 regulates mucous cell 
metaplasia by modulating levels of CLCA-3 in the Ada-/- mice. 
The results in this chapter demonstrate that IL-6 is produced in an 
adenosine-dependent manner largely from alveolar macrophages.  This appears 
to be sufficient to induce STAT-3 activation on alveolar epithelial cells.  
Functionally, IL-6 has important roles in Ada-/- mice.  Genetic removal or 
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neutralization of IL-6 in this model led to improved lung phenotypes in particular 
reduced inflammation, decreased airway enlargement, and diminished fibrosis.  
Although these results demonstrate that IL-6 contributes to the pulmonary 
phenotypes in the Ada-/- mice, analysis of IL-6 in pulmonary pathologies needs to 
be further extended to more conventional models in order to promote the 
development of novel IL-6 therapies.    
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CHAPTER FOUR 
THE ROLE OF IL-6 IN 
BLEOMYCIN-INDUCED 
PULMONARY FIBROSIS  
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INTRODUCTION 
In the previous chapter, it was demonstrated that the genetic removal of 
IL-6 and the IL-6 neutralization in Ada-/- mice resulted in decreased lung 
inflammation and fibrosis in association with decreased STAT-3 activation in 
alveolar airway epithelial cells.  This implies that STAT-3 activation via IL-6 
signaling is a mechanism of action that contributes to the development and 
progression of pulmonary inflammation and fibrosis in Ada-/- mice.   
In this chapter, to further confirm the contribution of IL-6 to inflammation 
and fibrosis in chronic lung diseases, I will utilize the bleomycin model, which is 
the most commonly used model to study pulmonary fibrosis.  As with Ada-/- mice, 
I will use both a genetic and pharmacological approach to investigate the role of 
IL-6 in this model.  The neutralization and genetic studies from both models will 
serve as confirmatory and/or complementary assays to evaluate the role of IL-6 
in adenosine-dependent pulmonary injury and fibrosis. 
 
INTRAPERITONEAL BLEOMYCIN-INDUCED PULMONARY FIBROSIS 
The most common method to deliver bleomycin is intra-tracheal (i.t.) 
administration (155).  The i.t. administration of bleomycin is a model of acute 
injury followed by resolvable fibrosis, which is inconsistent with human disease.  
This method is performed on 10-week old female mice exposed to a single i.t. 
dose of 2.5 U/kg bleomycin.  I.T bleomycin administration directly into the 
respiratory tract results in extensive apoptosis of airway epithelial cells.  This 
acute damage results in an injury phase characterize by the influx of 
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inflammatory cells by Day 7 post-challenge. However, by Day 21 post-challenge, 
inflammation has resolved and fibrosis is at its maximum.  This method results in 
a non-homogenous delivery of bleomycin that results in patchy fibrosis.  
Furthermore, due to the single delivery, the pulmonary fibrosis is temporal and 
resolves by Day 48 post-challenge.  This model does not represent what 
happens in the lungs of IPF patients.  In contrast, repeated intra-peritoneal (i.p.) 
injections of bleomycin are associated with diminished acute injury and 
progressive and irreversible pulmonary fibrosis.  Thus, the i.p. bleomycin model 
resembles to a greater extent what is observed in IPF.  For this reason, we will 
use the i.p. bleomycin model in our analysis of the contribution of IL-6 to 
pulmonary pathology. 
 
GENETIC REMOVAL OF IL-6 IN THE BLEOMYCIN MODEL 
C57BL/6J male mice at four to five weeks of age were challenge with 
bleomycin (0.035 U/g) via i.p. injection.  Established models revealed that male 
mice exhibit improved survival rates compared to females under the 
intraperitoneal injections (128).  Therefore, only male mice were used in our i.p. 
model.  To further understand the role of IL-6 in the development of pulmonary 
fibrosis, wild type mice and IL-6 knockout mice (IL-6-/-) were challenged with 
bleomycin via i.p. administration.  Mice were injected with bleomycin at Day 1, 4, 
8, 11, 15, 18, 22, and 25.  These mice were sacrificed at Day 33 post-initial 
challenge.  Control groups were injected with phosphate buffered saline (PBS) 
instead of bleomycin (Fig 4.1).  These studies were designed to further expand 
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our overall understanding of the contribution of IL-6 in experimental pulmonary 
fibrosis.   
 
IL-6 NEUTRALIZATION IN THE BLEOMYCIN MODEL 
To confirm the role of IL-6 in the development of pulmonary fibrosis, 
neutralization of IL-6 was performed in mice subjected to the i.p. bleomycin 
model.  Control groups were injected with PBS instead of bleomycin.  To assess 
the therapeutic potential of IL-6 neutralization in this model, wild type mice were 
treated subcutaneously with anti-IL-6 antibodies (30 mg/kg).  The anti-IL-6 
injections were performed on Day 15, 18, 22, and 25.  These animals were 
sacrificed at Day 33 after the initial injection.  It is important to note that 
pulmonary fibrosis is established by this stage in the protocol (Fig 4.1).  Thus, 
these studies were designed to assess the ability of IL-6 neutralization to halt and 
resolve active fibrosis. 
 
SPECIFIC QUESTIONS AND EXPERIMENTAL RATIONALE 
The implementation of a second model to study the role of IL-6 in 
pulmonary phenotypes results from the complementation of these two models. 
Ada-/- mice are an adenosine-dependent model of lung injury.  Thus, the 
pulmonary phenotype displayed by Ada-/- mice can be prevented and reversed by 
lowering adenosine levels with ADA enzyme replacement therapy (119).  These 
findings suggest that elevations of adenosine regulate pathways that promote the 
pathogenesis of chronic lung diseases. Hence, the ADA-deficient mouse is a 
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valuable tool to study the in vivo physiology of increased adenosine levels 
whereby establishing an adenosine-dependent model for chronic lung diseases.  
However, the elevation of the ADA substrates, namely adenosine and 2’-
deoxyadenosine, in Ada-/- mice results in a severe immunodeficiency similar to 
ADA deficiency in humans (64).  In addition, the phosphorylation of 2’-
deoxyadenosine leads to high levels of dATP, which induces apoptosis in 
lymphocytes (64).  The bleomycin mice model will compensate for the observed 
lymphopenia in the Ada-/- mice.  The bleomycin model is a useful as a tool for the 
study pulmonary fibrosis (40). Bleomycin is currently used as a chemotherapeutic 
agent, but side effects include impaired lung function and pulmonary toxicity 
resulting in pulmonary fibrosis (156).  Thus, this side-effect increases its 
relevance in studying pulmonary fibrosis.  However, IPF, as the name implies, 
results from unknown causes.  Therefore, the bleomycin model is one way of 
developing fibrosis, but not the only way.  This is corroborated with the vast anti-
fibrotic agents that are able to reduce fibrosis in the bleomycin model, but are not 
successfully translated into clinical relevance in humans (40).  Thus, studying the 
development of fibrosis in the Ada-/- mice is a complementary way to identify 
overlapping mechanisms underlying the development of pulmonary fibrosis in 
response to heterogeneous stimuli. 
Similar to the Ada-/- mice, the bleomycin model shows elevations of 
adenosine and IL-6.  This suggests that IL-6 plays a significant role in disease 
progression in these models.  As was shown in the previous chapter, the role of 
IL-6 in adenosine-mediated pulmonary injury was determined via complementary 
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and confirmatory assays through genetic and neutralization studies.  Thus, the 
neutralization and genetic studies from both models serve as confirmatory and 
complementary assays to evaluate the role of IL-6 in these models of adenosine-
dependent pulmonary injury and fibrosis. 
 
RESULTS 
REDUCED PULMONARY INFLAMMATION, FIBROSIS AND STAT-3 
ACTIVATION IN IL-6-DEFICIENT MICE EXPOSED TO BLEOMYCIN 
 
PULMONARY PATHOLOGY IN IL-6 KNOCKOUT MICE TREATED WITH 
BLEOMYCIN 
 
Adenosine is able to induce pro-fibrotic effects in the setting of prolonged 
elevations (79).  Bleomycin-induced pulmonary fibrosis is associated with 
increased adenosine levels and attenuation of fibrosis is observed with 
adenosine-based therapies (79).  To assess the role of IL-6 in the bleomycin 
model, IL-6 knock out mice were subjected to i.p. exposure of bleomycin twice a 
week for four weeks.  Examination of lung histopathology at the end of the 
protocol revealed that IL-6-/- mice exposed to bleomycin had reduced pulmonary 
injury (Fig 4.2).  These findings suggest that IL-6 contributes to the development 
and progression of pulmonary fibrosis in the bleomycin model.   
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Figure 4.1 
Schematic Diagram of Methodology Employed in the Bleomycin Model.   
To determine the role of IL-6 in the bleomycin model two approaches were 
utilized.  The genetic studies consisted of treating C57BL/6J mice (WT) and IL-6 
knock out male mice (IL-6-/-) at four to five weeks of age with bleomycin (0.035 
U/g) via intra-peritoneal injections.  After the fifth week of age, bleomycin 
injections were performed at Day 1, 4, 8, 11, 15, 18, 22, and 25.  PBS treated 
mice were used as a control group.  For the neutralization studies, C57BL/6J 
mice exposed to bleomycin as described above were treated subcutaneously 
with the anti-IL-6 antibody (30 mg/kg) on Day 15, 18, 22, and 25.  All of these 
animals were sacrificed at Day 33 after the initial injection.  Isotype antibody 
treated mice were used as a control group.   
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Figure 4.2 
Pulmonary phenotypes following intraperitoneal bleomycin exposure in IL-
6 knock out mice.   
To determine the role of IL-6 in the bleomycin model, the genetic studies 
consisted of treating C57BL/6J mice (WT) and IL-6 knock out male mice (IL-6-/-) 
at four to five weeks of age with bleomycin via intraperitoneal injections for four 
weeks twice a week.  Inflammatory and fibrotic characteristics were assessed 
from lung sections collected 33 days after initial bleomycin exposure.  This figure 
displays representative histology of lungs from wild type mice treated with PBS 
(top left) and bleomycin (bottom left) and IL-6-/- mice exposed to bleomycin 
(bottom right).  Examination of lung histology through H&E staining revealed that 
IL-6-/- mice exposed to bleomycin displayed a reduction in lung inflammation and 
pulmonary fibrosis.  Images are representative of 8 animals from each group.  
Scale bars: 200 µm. 
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PULMONARY INFLAMMATION IN IL-6 KNOCKOUT MICE TREATED WITH 
BLEOMYCIN 
 
To assess the role of IL-6 on inflammation in the bleomycin model, wild 
type and IL-6-/- mice were exposed with bleomycin.  Pulmonary inflammation was 
reduced (Fig. 4.3a-c) in IL-6-/- mice subjected to bleomycin.  Quantification of the 
level of inflammation in the BAL demonstrated a significant reduction in total cells 
(Fig 4.3a), and cellular differentials revealed reduction in macrophages (Fig 4.3b) 
and lymphocytes, eosinophils, and neutrophils (Fig 4.3c).  This suggests that in 
the bleomycin model, IL-6 contributes to pulmonary inflammation.  
 
 
PULMONARY FIBROSIS IN IL-6 KNOCKOUT MICE EXPOSED TO 
BLEOMYCIN 
 
Although there are numerous animal models of pulmonary fibrosis, 
perhaps the most appropriate is the i.p. bleomycin model.  This model develops 
similar features of IPF including intra-alveolar buds, mural incorporation of 
collagen, and obliteration of the alveolar space (140).  To assess the role of IL-6 
in bleomycin-induced fibrosis, IL-6-/- mice were treated with bleomycin for four 
weeks twice a week.  In comparison to bleomycin treated wild type mice, IL-6-/- 
mice exposed to bleomycin develop decreased collagen production (Fig 4.12a) 
and myofibroblast accumulation (Fig 4.12b).  This reduction in fibrosis was 
confirmed using Ashcroft scoring (Fig 4.12c).  These findings suggest that IL-6 
contributes to the development of pulmonary fibrosis in the intra-peritoneal model 
of bleomycin-induced injury.   
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Figure 4.3  
Pulmonary inflammation following intraperitoneal bleomycin exposure in 
IL-6 knock out mice.   
 
Bronchoalveolar lavage (46) was performed on C57BL/6J mice (WT) and IL-6 
knock out male mice (IL-6-/-) treated with bleomycin. (a) Total cells numbers in 
lavage fluid were counted using a hemocytometer.   BAL cells were cytospun and 
stained with Diff-Quick, allowing for determination of macrophages (b) and 
lymphocytes, eosinophils, and neutrophils (c).  Data are presented as mean cell 
counts ± SEM, n≥8. (*, p ≤ 0.05 WT PBS vs. WT bleomycin and #, p ≤ 0.05 WT 
bleomycin vs. IL-6 -/- bleomycin). 
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Figure 4.4  
Pulmonary fibrosis following intraperitoneal bleomycin exposure in IL-6 
knock out mice.   
 
Fibrotic assessment was performed on C57BL/6J  mice (WT) and IL-6 knock out 
male mice (IL-6-/-) treated with bleomycin. (a) Soluble collagen protein levels 
were measured using Sircol Assay.  Data presented as mean µg collagen/ml 
BAL fluid ± SEM, n≥8. (*, p ≤ 0.05 WT PBS vs. WT bleomycin and #, p ≤ 0.05 WT 
bleomycin vs. IL-6 -/- bleomycin).  (b) Lung sections were stained with an 
antibody against for α-SMA to visualize myofibroblast accumulation (pink stain).  
Images are representative of 6 animals from each group.  Scale bars: 100 µm. 
(c) Ashcroft scores were used to determine the degree of fibrosis (*, p ≤ 0.05 WT 
PBS vs. WT bleomycin and #, p ≤ 0.05 WT bleomycin vs. IL-6 -/- bleomycin, n≥6).   
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STAT-3 ACTIVATION IN AIRWAY EPITHELIAL CELLS IN MICE EXPOSED 
TO BLEOMYCIN 
 
Cellular activation of IL-6 involves phosphorylation of STAT-3 in target 
cells to induce different biological processes (90).  To evaluate the cellular 
targets of IL-6 activation in the intra-peritoneal bleomycin model, western blot 
analysis was conducted on whole lung lysates at Day 33 of the protocol.  Results 
revealed a significant reduction in STAT-3 activation in IL-6-/- mice exposed to 
bleomycin in comparison to wild type mice (Fig 4.5a).  Immunolocalization of 
phospho-STAT-3 in wild type mice exposed to bleomycin revealed activation of 
alveolar  epithelial  cells  next  to  fibrotic  foci; presumably hyperplastic epithelial 
cells (Fig 4.5c).  The increased STAT-3 activation in these cells was reduced in 
IL-6 -/- mice.  These results are similar to the findings observed in Ada -/- mice 
where the genetic removal or neutralization of IL-6 leads decreased pulmonary 
inflammation and fibrosis in association with decreased STAT-3 activation in 
alveolar epithelial cells (Chapter 3).  These observations suggest that the IL-6 
induced STAT-3 activation is associated with the regulation of pulmonary fibrosis. 
 
 
REDUCED PULMONARY INFLAMMATION, FIBROSIS AND STAT-3 
ACTIVATION FOLLOWING IL-6 NEUTRALIZATION IN MICE EXPOSED TO 
BLEOMYCIN 
 
PULMONARY PATHOLOGY IN BLEOMYCIN-EXPOSED MICE FOLLOWING 
IL-6 NEUTRALIZATION 
 
The bleomycin model is widely used in the assessment of antifibrotic 
compounds.  Furthermore, IL-6 deficiency suggests a pro-fibrotic role of IL-6.  
Thus,  to  examine  the  therapeutic  benefit of targeting IL-6 in the i.p. model of   
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Figure 4.5  
STAT-3 activation following genetic removal of IL-6 in bleomycin treated 
mice.  
 
Phospho-STAT-3 expression. (a) Western Blot analysis was performed using an 
antibody against phospho-STAT-3 in whole lungs lysates.  STAT-3 andα-actin 
were used as controls.  (b) Phospho-STAT-3 band intensity was quantified using 
ImageJ analysis.  Values are presented as the percentage of α-actin ± SEM, 
n≥4. (*, p ≤ 0.05 WT PBS vs. WT bleomycin and #, p ≤ 0.05 WT bleomycin vs. IL-
6 -/- bleomycin).  (c) Immunolocalization of phospho-STAT-3 expression. Lung 
sections were stained with an antibody specific for phospho-STAT-3 on alveolar 
epithelial cells (blue arrows). Images are representative of 8 animals from each 
group.  Scale bars: 100 µm. 
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bleomycin injury, wild type mice exposed to bleomycin were treated with IL-6 
neutralizing antibodies beginning at the stage after which fibrosis was 
established.  Histopathologic features of lung injury were reduced in bleomycin-
exposed mice subjected to IL-6 neutralization (Fig 4.6). These findings suggest 
that IL-6 contributes to the development and progression of pulmonary fibrosis in 
the bleomycin model.  Furthermore, neutralization of IL-6 in this model indicated 
that IL-6-blocking agents could have therapeutic benefits on pulmonary fibrosis. 
  
PULMONARY INFLAMMATION IN BLEOMYCIN-EXPOSED MICE 
FOLLOWING IL-6 NEUTRALIZATION 
 
To quantify the reduced pulmonary inflammation observed on histologic 
findings, BAL was performed and recovered inflammatory cells were counted 
using a hemocytometer.  Results revealed characteristic increases in total 
inflammatory cells recovered from BAL fluid of wild type mice exposed to 
bleomycin versus PBS, but a significant reduction was observed with the use of 
IL-6 neutralizing antibodies (Fig 4.7).  Decreased pulmonary inflammation was 
observed by the reduction in total inflammatory cells (Fig 4.7a), macrophages 
(Fig 4.7b), lymphocytes, eosinophils, and neutrophils (Fig 4.7c).  These data 
suggest that IL-6 contributes to pulmonary inflammation in the bleomycin model. 
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Figure 4.6 
Pulmonary phenotypes following intraperitoneal bleomycin exposure in 
mice treated with IL-6 neutralization antibodies.  
To determine the role of IL-6 in the bleomycin model, the neutralization studies 
consisted of treating C57BL/6J  male mice at four to five weeks of age with 
bleomycin via intraperitoneal injections for four weeks twice a week.  At the same 
time, these mice were treated subcutaneously with the anti-IL-6 antibody (30 
mg/kg).  The anti-IL-6 injections were performed on Day 15, 18, 22, and 25.  
Inflammatory and fibrotic characteristics were assessed from lung sections 
collected 33 days after initial bleomycin exposure.  This figure displays 
representative histology of lungs from wild type mice treated with saline (top left) 
and bleomycin-exposed mice treated with isotype antibody (bottom left) or IL-6 
antibody (bottom right).  Examination of lung histology through H&E staining 
revealed that neutralization of IL-6 displayed a reduction in lung inflammation and 
pulmonary fibrosis.  Images are representative of 8 animals from each group.  
Scale bars: 200 µm.  
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Figure 4.7 
Pulmonary inflammation following intraperitoneal bleomycin exposure in 
mice treated with IL-6 neutralization antibodies.  
Bronchoalveolar lavage (46) was performed on bleomycin-exposed mice treated 
with IL-6 neutralizing antibodies or isotype.  Total cells numbers (a) and cellular 
differentials including macrophages (b) and lymphocytes, eosinophils, and 
neutrophils (c).  Data are presented as mean cell counts ± SEM, n≥8. (*, p ≤ 0.05 
PBS + IL-6 Antibody vs. Bleomycin + Isotype and #, p ≤ 0.05 Bleomycin + 
Isotype vs. Bleomycin + IL-6 Antibody). 
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PULMONARY FIBROSIS IN BLEOMYCIN-EXPOSED MICE FOLLOWING IL-6 
NEUTRALIZATION 
 
To assess the therapeutic benefit of targeting IL-6 on pulmonary fibrosis, 
bleomycin-exposed mice were treated with IL-6 neutralizing antibodies.  Results 
revealed that IL-6 neutralization was associated with decreased pulmonary 
damage (Fig 4.6).  In addition, wild type mice exposed to bleomycin displayed 
characteristics increases in collagen production and deposition and myofibroblast 
accumulation.  However, treatment with IL-6 neutralizing antibodies at the stage 
of established fibrosis attenuated collagen production (Fig 4.8a), and 
myofibroblast accumulation (Fig 4.8c).  These changes were associated with 
significant reduction in the quantification of pulmonary fibrosis as determined by 
Ashcroft scores (Fig 4.8d).  Moreover, physiological analysis measuring arterial 
oxygen saturation demonstrated that IL-6 neutralization was associated with 
restored oxygen saturation in this model (Fig 4.8b).  These observations suggest 
that IL-6 is a promising antifibrotic agent able to reduce pulmonary fibrosis and 
preserve clinically relevant properties such as arterial oxygen saturation. 
 
IL-6 DEPENDENT STAT-3 ACTIVATION IN EPITHELIAL CELLS IN 
BLEOMYCIN-EXPOSED MICE 
 
Similar findings regarding the increased activation of STAT-3 in this model 
were determined by western blot analysis (Fig 4.9).  Moreover, results 
demonstrated significant reduction in STAT-3 activation following anti-IL-6 
treatment (Fig 4.9a, b).  Identification of cellular targets via immunolocalization of 
phospho-STAT-3  demonstrated  an  increased  activation  in  alveolar epithelial  
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Figure 4.8 
Pulmonary fibrosis following intraperitoneal bleomycin exposure in mice 
treated with IL-6 neutralization antibodies.  
(a) Soluble collagen protein levels were measured using Sircol Assay.  Data 
presented as mean µg collagen/ml BAL fluid ± SEM, n≥8. (*, p ≤ 0.05 PBS + IL-6 
Antibody vs. Bleomycin + Isotype and #, p ≤ 0.05 Bleomycin + Isotype vs. 
Bleomycin + IL-6 Antibody).  (b) Measurement of arterial oxygen saturation.  
Data presented as percentage of oxygen saturation ± SEM, n≥10 (*, p ≤ 0.05 
PBS + IL-6 Antibody vs. Bleomycin + Isotype and #, p ≤ 0.05 Bleomycin + 
Isotype vs. Bleomycin + IL-6 Antibody).  (c) Lung sections were stained with an 
antibody against for -SMA to visualize myofibroblast accumulation (pink stain).  
Images are representative of 6 animals from each group.  Scale bars: 100 µm. 
(d) Ashcroft scores were used to determine the degree of fibrosis (*, p ≤ 0.05 
PBS + IL-6 Antibody vs. Bleomycin + Isotype and #, p ≤ 0.05 Bleomycin + 
Isotype vs. Bleomycin + IL-6 Antibody, n≥6). 
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Figure 4.9 
STAT-3 activation following neutralization of IL-6 in bleomycin treated 
mice.  
 
Phospho-STAT-3 expression.  (a) Western Blot analysis was performed using an 
antibody against phospho-STAT-3 in whole lungs lysates.  STAT-3 andα-actin 
were used as controls.  (b) Phospho-STAT-3 band intensity was quantified using 
ImageJ analysis.  Values are presented as the percentage of α-actin ± SEM, 
n≥4. (*, p ≤ PBS + IL-6 Antibody vs. Bleomycin + Isotype and #, p ≤ 0.05 
Bleomycin + Isotype vs. Bleomycin + IL-6 Antibody).  (c) Immunolocalization of 
phospho-STAT-3 expression. Lung sections were stained with an antibody 
specific for phospho-STAT-3 on alveolar epithelial cells (blue arrows). Images 
are representative of 8 animals from each group.  Scale bars: 100 µm. 
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cells.  Moreover, this activation was reduced following IL-6 neutralization (Fig 
4.9c).  These results indicate that IL-6 acts as a pro-fibrotic cytokine in this model 
and contributes to the development of pulmonary inflammation and fibrosis, and 
neutralization of IL-6 is associated with the reduction of fibrotic features and 
STAT-3 activation in alveolar epithelial cells. 
 
DISCUSSION 
In this chapter, the contribution of IL-6 to pulmonary fibrosis was 
demonstrated in the i.p bleomycin model.  Compared to other methods of 
bleomycin administration, the i.p. bleomycin model develops pulmonary fibrosis 
that resembles more adequately what is observed in human disease.   Repeated 
i.p. bleomycin injections develop mild acute injury and progressive and 
irreversible pulmonary fibrosis.  In Chapter 3, the focus was on the determination 
of the contribution of IL-6 to pulmonary phenotypes in Ada-/- mice.  It was 
demonstrated that IL-6 was able to regulate pulmonary inflammation, airspace 
destruction, and pulmonary fibrosis.  However, to further corroborate the role of 
IL-6 in pulmonary disorders, the implementation of a second disease relevant 
model was necessary.  For this reason, the contribution of IL-6 in the i.p. 
bleomycin model was determined.  Genetic studies determined that IL-6-/- mice 
exposed to bleomycin exhibit attenuation of pulmonary fibrosis.  Moreover, to test 
the pharmacological approach, bleomycin-exposed mice were treated with IL-6 
neutralizing antibodies.  This therapeutic approach indicated significant efficacy 
of neutralizing IL-6 in the bleomycin model during established fibrosis.  This 
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demonstrated that neutralization of IL-6 is able to attenuate the development and 
progression of pulmonary fibrosis in the bleomycin model.       
Patients with IPF exhibit varying degrees in inflammation and airway 
fibrosis with excessive fibroblast proliferation, myofibroblast differentiation, and 
extracellular matrix deposition (157).  IPF is characterized by the development of 
fibroblastic foci and repetitive alveolar epithelial injury, which culminates in 
regenerative hyperplastic type II and loss of type I pneumocytes.  Myofibroblast 
accumulation is thought to arise from proliferation and differentiation of resident 
fibroblasts, from bone-marrow derived circulating fibrocytes that serve as 
progenitors for interstitial fibroblasts, and from the process known as epithelial-to-
mesenchymal transition (EMT).  EMT refers to the process where epithelial cells 
are capable of undergoing a reversible switch from an epithelial to mesenchymal, 
fibroblast-like phenotype resulting in α-SMA expression, ECM deposition, 
myofibroblast accumulation, and fibrosis (158). We demonstrated that IL-6 
deficiency and neutralization reduced pulmonary fibrosis in both Ada-/- mice and 
the bleomycin model.  Our findings support previous statements implicating IL-6 
in the regulation of fibrosis.  In response to aerosolized antigen, IL-6 deficiency 
attenuates subepithelial fibrosis independently of inflammation (159).  Also, 
transgenic mice overexpressing IL-6 in the airways develop subepithelial fibrosis, 
myofibroblast hyperplasia, and airway thickening (120).  IL-6 is also able to 
induce hepatic myofibroblast proliferation (160).  In the i.t. bleomycin model, IL-6 
deficiency attenuates fibrotic distortion of lung architecture, decreases collagen 
content, and downregulates TGF-β and MCP-1 (124).  Based on our findings, IL-
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6 deficiency and neutralization in both models is associated with decreased 
macrophages and neutrophils, which could in part explain the attenuation in 
fibrotic changes since these inflammatory cells are known to produce pro-fibrotic 
mediators.  In addition, different CC chemokines, such as MCP-1 and MCP-5, 
have been implicated in the trafficking of fibrocytes and contribution of fibrosis 
(161).  Downregulation of MCP-1 and other chemoattractants via IL-6 
neutralization provide a possible explanation of the attenuation of fibrosis.   
Another possible molecular pathway by which IL-6 effects fibrosis include 
its role on fibroblasts.  IL-6 promotes growth-arrest in fibroblasts from normal 
patients, whereas in fibroblasts from IPF patients IL-6 induces proliferative and 
anti-apoptotic effects (126), suggesting that IL-6 may inhibit fibrosis in normal 
conditions but in the setting of fibrosis IL-6 exacerbates disease conditions.  
Furthermore, it has been shown that activation of A2BR in human lung fibroblasts 
leads to IL-6 production inducing myofibroblasts differentiation (28).  This 
adenosine-dependent myofibroblast differentiation process was also prevented 
using an IL-6 neutralizing antibody.  Another study demonstrated that exposure 
of cardiac fibroblasts with IL-6, and the sIL-6Rα leading to IL-6 trans-signaling, 
promotes collagen production and myofibroblast differentiation (162).  
Furthermore, studies in IL-6 deficient mice upon wound exposure demonstrated 
that IL-6 modulates α-SMA expression on dermal fibroblasts (163); and that IL-6 
has the ability to modulate TGF-β and TGF-βR2 in the skin and dermal 
fibroblasts suggesting an association in fibrotic pathologies between IL-6 and 
TGF-β (164).  Thus, these previous reports and our current findings further 
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corroborate the role of IL-6 on fibrosis.  The involvement of IL-6 in myofibroblast 
differentiation and extracellular matrix deposition is a possible mechanism by 
which IL-6 regulates the pathogenesis or maintenance of pulmonary fibrosis.  
Thus, it is conceivable that IL-6 contributes to the progression of pulmonary 
fibrosis as a pro-inflammatory cytokine by modulating immune responses that 
augment fibrosis and as a pro-fibrotic cytokine by exerting direct effects on target 
cells such as myofibroblast differentiation and extracellular matrix production.  
Our findings implicate a direct role by which distorted IL-6 signaling, be it 
classical or trans-signaling, or a combination of both, contribute to profibrotic 
effects that exacerbate pulmonary fibrosis. 
In conclusion, the results presented in this chapter suggest that IL-6 
regulates aspects of bleomycin-induced and adenosine-mediated pulmonary 
fibrosis.  Furthermore, the therapeutic approach presented in this chapter 
indicates that IL-6-based therapies might be beneficial for patients with 
pulmonary fibrosis.  In addition, STAT-3 activation points to a potential 
mechanism in alveolar epithelial cells by which IL-6 mediates pulmonary fibrosis.  
We need to conduct further studies in vitro to investigate the mechanisms by 
which IL-6 is able to induce fibrosis.  Additionally, the findings in our models 
regarding the role of IL-6 in regulating fibrosis need to be translated into human 
disease for clinical relevance.  These important aspects will be addressed in the 
next chapter.    
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CHAPTER FIVE 
INVESTIGATION OF MECHANISMS 
OF IL-6 MEDIATED PULMONARY 
FIBROSIS 
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INTRODUCTION 
PULMONARY FIBROSIS AND EPITHELIAL-TO-MESENCHYMAL 
TRANSITION (EMT)  
 
Our understanding of the mechanisms underlying the pathogenesis of 
pulmonary fibrosis remains elusive.  Originally it was believed that the 
development of pulmonary fibrosis was the result of chronic inflammation.  This 
was accepted because the existence of immune-derived secreted factors that 
stimulate fibroblast growth, such as transforming growth factor (TGF)-β and 
platelet-derived growth factor (PDGF) (165).  However, it is now evident that 
inflammation and fibrosis are often not directly associated.  Therefore, 
subsequent theories speculate that without preceding inflammation, fibrosis 
develops as a result of constant epithelial injury and from an impaired wound 
repair process (157).  Following tissue injury, inflammatory and host tissue repair 
responses are evoked to initiate recruitment, activation, apoptosis, and clearance 
of effector cells.  Yet, fibrosis is now thought of as the consequence of a 
dysregulated repair processes that are constitutively “turned on” while the 
inflammatory response is either reduced or “switched off” (2).  Hence, these 
repair processes remain dysregulated while inflammation ceases at chronic 
fibrotic stages. 
Pulmonary fibrosis can develop progressively as the result of constant 
lung injury or it can arise spontaneously from an unknown cause, hence the 
name idiopathic pulmonary fibrosis (IPF).  Sustained alveolar epithelial damage 
leads to respiratory failure due to severe distortion of lung architecture.  This lung 
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architectural damage drives enhanced myofibroblast proliferation and activation 
resulting in excessive extracellular matrix (ECM) deposition in the lung 
interstitium (158).  The myofibroblast is considered to be the primary effector cell 
of pulmonary fibrosis.  However, the origin of the myofibroblast in the injured lung 
is not clearly established.  Three potential sources have been hypothesized for 
the observed myofibroblast accumulation and differentiation.  These are: i) 
proliferation and conversion of resident lung fibroblasts into myofibroblasts; ii) 
bone-marrow derived circulating fibrocytes, which serve as progenitors for 
interstitial fibroblast and differentiate into myofibroblasts; and iii) a process known 
as “epithelial-mesenchymal transition” (EMT) resulting in myofibroblast 
accumulation from epithelial progenitors.  These different sources of 
myofibroblasts support the notion that fibrosis occurs independently of 
inflammation as the result of an abnormal wound healing response and constant 
epithelial injury. 
The third hypothesis states that the contribution from the process known 
as EMT results in myofibroblast accumulation in the lung.  In the context of 
pulmonary fibrosis, EMT is a process where type II alveolar epithelial cells 
(AECs) are capable of undergoing a form of metaplasia by switching from an 
epithelial to fully differentiated mesenchymal, fibroblast-like phenotype (166) (Fig 
5.1).   For clarity, type II AECs are able to differentiate into type I AECs to allow 
for re-epithelialization, a process known as trans-differentiation (167).  It is 
important to note that the EMT process is involved in cellular transdifferentiation 
during development and tumor progression.  During development, epiblasts 
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undergo EMT to form primary mesenchyme and secondary epithelia are created 
through EMT in order to form fully differentiated adult epithelia or other cell types 
(168).  During tumor progression, through EMT, epithelial cells are able to lose 
polarity, disassemble cell adhesion systems, produce cell-motility systems, and 
change location (169).    
In the setting of pulmonary fibrosis, EMT is involved in the fibrotic 
processes by promoting the loss of the epithelial phenotype and favoring 
myofibroblast differentiation.  TGF-β is known to induce α-smooth muscle actin 
(α-SMA) expression, serving as a key indicator of myofibroblast differentiation 
from fibroblasts.  TGF-β is an important cytokine that regulates cell growth, 
morphogenesis, cell differentiation, apoptosis, (170) and fibrosis (171).  TGF-β is 
recognized as a “master switch” of fibrosis.  In addition to TGF-β, soluble growth 
factors such as epidermal growth factor (EGF), hepatocyte growth factor (HGF), 
and fibroblast growth factors (FGF), have also been demonstrated to play a role 
in EMT (172).  Nevertheless, upon the influence of these factors EMT occurs in a 
reversible manner.   However, only prolonged exposure of TGF-β is able to 
induce complete EMT (172).   In epithelial cells, treatment with TGF-β  leads to 
activation of transcription factors, such as Smads, Slug, Snail, Scatter, lymphoid 
enhancing factor-1 (LEF-1), and β-catenin (168).  TGF-β can also activate non-
Smad mediated cellular signaling pathways, such as Rho kinase to rearrange the 
cytoskeleton and down-regulate E-cadherin (173).  Thus, the “EMT proteome” is 
activated to induce junctional disassembly, cytoskeletal rearrangement,  and  
cellular  motility   (174).     
  
 
 
Figure 5.1 
Epithelial to Mesenchymal Transition (EMT)
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In addition,  cross-talk  between classical pathways (TGF-β and Rho) and 
other signaling molecules (Ras, ERK, MAPK, Notch, Wnt proteins, NF-κβ, and 
PI3K) have been implicated to play a role regarding the effect or reversibility of 
EMT in the fibrotic response (174).  Despite the extensive studies regarding EMT 
and TGF-β in fibrosis, there is still a knowledge gap in the pathobiology and 
biogenesis of pulmonary fibrosis that renders this disorder untreatable.  Thus, to 
address this knowledge gap in pulmonary fibrosis, in this dissertation I focus on 
an alternative signaling pathway that could promote the accumulation of the 
fibroblasts and myofibroblasts in the injured lung.  This chapter focuses on the 
role of IL-6 trans-signaling in mediating EMT and fibrosis. 
The identification of fibroblasts and myofibroblasts that have differentiated 
from epithelium consists of analysis in morphologic changes, acquisition of 
mesenchymal phenotype, and loss of epithelial characteristics.  The 
morphological change in EMT consists of the modification from a cuboidal cell 
shape (AEC II) to an elongated or spindle-shaped form (fibroblast/myofibroblast).  
The acquisition of fibroblast- or myofibroblast-specific markers consists of 
fibroblast specific protein (FSP-1) and α-SMA, respectively.  The loss of epithelial 
phenotype includes down-regulation of E-cadherin, cytokeratins, surfactant 
protein C (SPC), thyroid transcription factor-1 (TTF-1), and zonula occludens-1 
(ZO-1) (175).  Regarding differentiation, the myofibroblast is the intermediate cell 
type between the fibroblast and smooth muscle cell.  To distinguish fibroblast 
from myofibroblasts it is important to note that fibroblasts might contain actin in 
their cortex similar to proto-myofibroblasts; however, fibroblasts neither express 
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stress fibers nor they are able to form adhesion with the extracellular matrix 
(176).  Thus, these are known as non-contractile fibroblasts.  Another 
characteristic feature is that fibroblasts express vimentin, but not desmin and α-
SMA (177).  Fibroblasts differentiate upon mechanical stress into proto-
myofibroblasts, which contain cytoplasmic actin-containing stress fibers 
terminating in fibronexus adhesion complexes, and are able to express cellular 
fibronectin and generate contractile force (176).  Stimulation of TGF-β increases 
ED-A fibronectin expression, which under mechanical stress will promote the 
differentiation of proto-myofibroblasts into myofibroblasts.  These myofibroblasts 
are characterized by de novo α-SMA expression, extensively developed stress 
fibers, increased fibronexus adhesion complexes, greater contractile force, and 
higher organization of extracellular fibronectin into fibrils (176).  Due to the 
heterogeneity in these cells, other markers to distinguish the myofibroblast 
include vimentin, yet α-SMA is the most widely accepted.  Although α-SMA 
expression is used to distinguish the myofibroblast, α-SMA is the most abundant 
protein in smooth muscle cells.    Distinction between the smooth muscle cell and 
the myofibroblast can be made due to the following: myofibroblasts have a 
surface characterized by fibronectin fibrils and fibronexus junctions, whereas the 
external lamina (basement membrane), attachment plaques, and plasmalemmal 
caveolae are typical of smooth muscle cells (177).  In addition, myofibroblasts 
can also be distinguished due to their lack of smooth muscle markers, such as 
desmin and smooth muscle myosin (178).  Thus, myofibroblasts identification 
consists of abundant rough endoplasmic reticulum, peripheral myofilaments with 
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focal densities (stress fibers), fibronexus junctions, and expression of α-SMA and 
vimentin (177).   
The fibroblasts are spindle shaped cells found in many tissues and 
organs.  Fibroblasts respond to and synthesize various cytokines, chemokines, 
and other mediators of inflammation, such as TGF-β-and PDGF (179).  
Fibroblasts also participate in the wound healing responses by producing ECM 
molecules, such as collagens, proteoglycans, fibronectin, tenascin, and laminin 
(178).  Fibroblasts also produce matrix metalloproteinases (MMPs) and tissue 
inhibitors of metalloproteinase (TIMP).  The production of these proteases and 
anti-proteases participate in the regulation of the ECM degradation (178).   In 
addition, fibroblasts also regulate tissue interstitial fluid volume and pressure via 
interaction of β1 integrin receptors.  Upon activation following tissue injury, 
fibroblasts differentiate into myofibroblasts.  Myofibroblasts in turn play a central 
role in wound healing and repair by participating in the physiological 
reconstruction of connective tissue after injury (180).  Myofibroblasts express α-
SMA containing stress fibers, whereby exert contractile force to reduce the size 
of the wound.   The final phases of remodeling consist of resolution of MMPs and 
TIMPs, ECM degradation, and myofibroblasts removal by apoptosis (178).  
Dysregulation of this repair mechanism leads to an abnormal and pathological 
wound healing response.  Thus, the dysregulation of injury repair response and 
myofibroblast function are responsible for generating the pathological tissue 
deformations, which are characteristic of fibrosis.  This dysregulation is 
responsible for myofibroblast accumulation.  In turn, the myofibroblast is 
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responsible of increased ECM deposition, altered tissue architecture, and 
impaired function (179). 
Many fibrotic diseases are associated with abnormal repair responses due 
to imposed tissue injury, such as traumatic/mechanical, environmental, 
infectious, cancerous, autoimmune, and/or drug-induced insults.  It is believed 
that myofibroblasts play a central role in the pathogenesis of idiopathic 
pulmonary fibrosis (IPF).  The pathogenesis of IPF is associated with increased 
numbers of fibroblastic foci and rapid development of fibrotic lesions, which are 
composed of proliferating myofibroblast.  These myofibroblasts are key 
mediators of ECM deposition, structural remodeling, and destruction of 
alveocapillary units upon lung injury (181).   The myofibroblast contributes to 
active fibrosis by its ability to express increased levels of collagen, contributing to 
high levels of ECM that constitutes tissue destruction and scar acquisition (181).  
Besides the role ECM deposition, myofibroblasts are a key source of fibrotic 
cytokines (TGF-β) and pro-inflammatory cytokines, such as the CC chemokine, 
monocyte chemotactic protein-1 (MCP-1).  Thus, this amplification of 
inflammation may result in a positive feedback loop intensifying the progression 
of fibrosis (181).  Another important aspect of the myofibroblast is its contractility, 
which is important in wound contraction and is responsible for the altered 
mechanical characteristic in pulmonary fibrosis (182).  Therefore, the persistence 
of myofibroblasts within a fibrotic lesion leads to the functional impairment of the 
affected organ due to the excessive scarring, which creates a honeycombing 
appearance (183).   Thus, dysregulation of fibroblast/myofibroblast function is 
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associated with features that affect tissue structure and function such as 
excessive ECM deposition and inappropriate tissue contraction.  Hence, 
understanding this dysregulation is critical to develop novel and effective 
therapies that address not only the symptoms but the progressive nature of 
pulmonary fibrosis.  In this dissertation, the role of IL-6 was determined as an 
alternative pathway involved in the development of pulmonary fibrosis.  
 
IL-6 IN PULMONARY FIBROSIS  
Significant efforts are conducted in order to identify significant roles of 
growth factors and cytokines involved in disease pathogenesis.  Thus, the role of 
the IL-6/gp130 family of cytokines has been suggested to play a role in the 
susceptibility and progression of pulmonary fibrosis (122).  Cytokines such as 
leukemia inhibitory factor (LIF), oncostatin M (OSM), IL-11, ciliary neurotrophic 
factor (CNTF), and cardiotrophin-1 (CT-1) belong to the IL-6 family of cytokines.  
These cytokines are comprised of a single chain polypeptide (~20 kb), which all 
engage the signal transducing unit gp130 (90).  The family of suppressor of 
cytokine signaling (SOCS) proteins is the main inhibitor of gp130 signaling via a 
classical negative feedback loop (184).  IL-6 is a pleiotropic cytokine with 
relevant effects on inflammation and fibrosis, yet its role in fibrosis remains 
unknown.  Profibrotic growth factors (i.e. TGF-β) are able to induce IL-6 release, 
which mediated cellular effects that might be attributed to the inductors of IL-6 
(185).  Regarding the fibrotic role of IL-6, studies have demonstrated that IL-6 is 
able to induce collagen production from dermal fibroblasts (125).  Also, patients 
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with systemic sclerosis demonstrate increased IL-6 production by mononuclear 
cells (186).  Human lung fibroblasts isolated from IPF patients respond 
abnormally to IL-6, which display mitogenic properties via sustained activation of 
ERK resulting in p27Kip1 inhibition and induction of cyclin D1 (187).  The 
response of normal fibroblasts to IL-6 was the opposite, mainly sustained STAT-
3 activation and production of cyclin-dependent kinase inhibitor p19INK4D 
resulted in the inhibition of proliferation (187).  Also, IL-6 is able to maintain 
normal fibroblasts in cell cycle arrest due to increase Bax expression, which 
promotes apoptosis (145).  However, in IPF fibroblasts, IL-6 is able to suppress 
apoptosis by inducing the expression of Bcl-2, which is an anti-apoptotic protein 
(187).  Thus, IL-6 is able to have various effects on normal cells and IPF 
fibroblasts depending on the pathway activated, either ERK or STAT-3, and the 
kinetics of the activation, either transient or sustained.  For example, in normal 
cells induces apoptosis via transient ERK and sustained STAT-3 activation; 
whereas in IPF fibroblasts, proliferation was induced via sustained ERK and 
transient STAT-3 activation (187).  These observations indicate that IL-6 
signaling via STAT-3 activation is dysregulated in human lung disease.  Thus, 
investigations of IL-6 signaling pathways are critical to further understand the 
pathogenesis of chronic lung diseases. 
Furthermore, mice overexpressing IL-6 in the lung are characterized with 
a diffuse peribronchial mononuclear cell inflammatory response (188).  Although 
these mice are resistant to airway hyperresponsiveness, minimal signs of fibrosis 
are observed.  Similar findings were observed in rats overexpressing IL-6 in the 
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airways, which induced lymphocytic alveolitis without proliferation of fibroblasts 
(189).  However, since IL-6 is an important cofactor in inflammatory cell 
recruitment and activation, indirect fibrotic contributions are easily overlooked.  
For example, IL-6 and TNFα together are able to regulate the expression of 
MIP1α, which is a profibrotic chemokine (123).  In the bleomycin model of 
pulmonary fibrosis, IL-6 is secreted by endothelial cells and macrophages in rats 
(190, 191).  However, the role of IL-6 and its interaction with other mediators at 
the setting or during the development of lung injury remains unknown.  As noted 
in previous chapters, IL-6 neutralization was shown to reduce fibrosis.  However, 
this effect was not demonstrated to be a direct cause of IL-6 neutralization.  This 
was the case since reduction of fibrosis via IL-6 neutralization was observed in 
conjunction with diminished levels of important chemokines and cytokines known 
to be mediators of fibrosis.  Thus, analysis of direct mechanisms by which IL-6 
induces fibrosis is addressed in this chapter.    
 
CLASSICAL VS IL-6 TRANS-SIGNALING 
In response to injury and infection, IL-6 is produced by different cells such 
as, mast cells, eosinophils, endothelial cells, smooth muscle cells, 
monocytes/macrophages, and B and T cells (88). In addition, IL-6 is able to 
induce autoimmunity, amplify acute inflammation, and develop chronic 
inflammation (89). Dysregulation of IL-6 signaling has been implicated in the 
onset and maintenance of several diseases, such as multiple sclerosis, 
inflammatory bowel disease, rheumatoid arthritis, and cancer (90). IL-6 signals 
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by binding to the membrane-bound IL-6 receptor mIL-6Rα, which is expressed 
predominantly on leukocytes and hepatocytes, and then associates with the 
signal-transducing gp130 protein in order to phosphorylate and dimerize STAT-3. 
Thus, phospho-STAT-3 is an indicator of IL-6-induced cellular activation. 
Phosphorylated STAT-3, once dimerized, is translocated into the nucleus to act 
as a transcription factor and regulate the expression of target gene (101).  STAT-
3 up-regulation and STAT-3 downstream targets also have been implicated in 
lung diseases (98, 102). This trans-signaling mechanism increases the spectrum 
of IL-6 activities from immune responses to involvement of chronic pathological 
states. Furthermore, elevations of the agonist sIL-6Rα have been reported in 
cancer and several chronic inflammatory and autoimmune diseases (112). 
Since the mIL-6Rα is only expressed on leukocytes and hepatocytes, 
evaluation of the IL-6 trans-signaling is required for proper understanding of IL-6 
biological activity. In the absence of mIL-6Rα cells are unresponsive to IL-6. The 
sIL-6Rα is able to associate with secreted IL-6 forming a complex with high 
affinity for gp130 thereby acting as an agonist by increasing the spectrum of IL-6 
activity (132). The signal transducing gp130 is ubiquitous expressed rendering 
cells otherwise unresponsive to IL-6 to become activated by the IL-6/sIL-6Rα 
complex. Accordingly, the agonist sIL-6Rα can be produced by two different 
mechanisms, by proteolytic cleavage (PC-sIL-6Rα) or by an alternatively spliced 
mRNA (AS-sIL-6Rα) (53).  In addition, both IL-6 and the sIL-6Rα are increased in 
numerous inflammatory diseases (98, 101, 102).  Thus, the mIL-6Rα is primarily 
associated with anti-inflammatory qualities, whereas the sIL-6Rα has been 
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associated in pathological conditions with pro-inflammatory properties (112).  For 
instance, in breast cancer patients IL-6 elevations correlates with poor survival 
(192).  Furthermore, it has been demonstrated that IL-6 through STAT-3 
activation mediates EMT in breast cancer cells via trans-activation of TWIST, a 
known metastatic regulator (193).  Although levels of IL-6 have been reported in 
chronic lung diseases, the role of IL-6 trans-signaling has not been fully 
investigated in particular in pulmonary fibrosis.  The purpose of this chapter is to 
elucidate the mechanism by which IL-6 trans-signaling can induce fibrosis.     
 
SPECIFIC QUESTIONS AND EXPERIMENTAL RATIONALE 
In conjunction with increases in levels of adenosine and IL-6, Ada-/- mice 
develop features of pulmonary fibrosis including the production and deposition of 
collagen (119).  In addition, adenosine and its stable analog, 5’-(N-
ethylcarboxamido)-adenosine (NECA), are able to activate the A2BR to increase 
IL-6 release and induce the differentiation of human lung fibroblasts to 
myofibroblasts, which can be attenuated with treatment of an IL-6 neutralizing 
antibody (28).  This suggests that IL-6 displays pro-fibrotic properties in the 
differentiation of fibroblast to myofibroblasts.  Furthermore, the previous chapters 
have demonstrated a pro-fibrotic role of IL-6 by attenuation of fibrosis in Ada-/- 
mice and bleomycin-exposed mice subjected to genetic removal or neutralization 
of IL-6.  Hence, the implied role of IL-6 in the differentiation of fibroblasts to 
myofibroblasts and the results from previous chapters indicate that IL-6 signaling 
is involved in regulating the fibrotic responses seen in Ada-/- mice and in the 
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bleomycin model.  However, the mechanism of action by which IL-6 confers 
fibrotic features remains unknown.  In addition, increased STAT-3 activation on 
alveolar epithelial cells was attenuated in association with decreased collagen 
deposition and reduced α1-procollagen expression in both models subjected to 
genetic removal and neutralization of IL-6.  To the best of our knowledge, 
alveolar epithelial cells do not express the mIL-6Rα suggesting that IL-6 trans-
signaling is inducing pro-fibrotic properties on these cells via STAT-3 activation.  
It has been shown that IL-6 trans-signaling induces EMT in cancer (193).  This 
chapter will address the mechanism by which IL-6 confers fibrotic characteristics 
and the role of IL-6 trans-signaling on pulmonary fibrosis.  Examination of EMT 
markers determined the role of IL-6 in the pathogenesis at least in vitro.  
Furthermore, characterization of IL-6 trans-signaling in the lungs of patients with 
COPD and IPF corroborated the findings in the mouse models employed in the 
previous chapters.   Hence, I demonstrate for the first time that IL-6 trans-
signaling represents a potential therapeutic application for pulmonary fibrosis.   
 
RESULTS 
ELEVATIONS OF SIL-6Rα IN MODELS AND PATIENTS WITH PULMONARY 
FIBROSIS 
 
IL-6 classical signaling involves the binding of IL-6 to membrane bound IL-
6Rα to initiate a conformational change that facilitates interaction with gp130 
signaling receptors to promote downstream signaling via STAT-3 
phosphorylation (90).  This pathway is abundant in cells derived from the 
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hematopoetic lineage and in hepatocytes (142).  The IL-6 trans signaling 
pathway involves the generation of an alternative splice isoform or the shedding 
of the mIL-6Rα to generated the sIL-6Rα.   In turn, IL-6 binds the sIL-6Rα and 
facilitates binding of this complex to gp130 on cells that lacks the mIL-6Rα (98).  
This IL-6 trans-signaling pathway has been implicated in the amplification of 
various inflammatory and chronic diseases (141), but has not been examined in 
pulmonary fibrosis.  To address this gap in our knowledge, an ELISA specific for 
sIL-6Rα was used and revealed a marked increase in sIL-6Rα levels in the 
lavage fluid from Ada-/- mice and mice exposed to bleomycin (Fig. 5.1).  Based 
on these observations, we hypothesized that IL-6 trans-signaling promotes EMT 
in airway epithelial cells through a pathway that involves STAT-3 activation.  
 
IL-6 TRAN-SIGNALING AND EMT IN HUMAN AND MURINE ALVEOLAR 
EPITHELIAL CELLS  
 
Elevations of sIL-6Rα in Ada-/- mice and in the bleomycin model indicate 
that IL-6 trans-signaling may be functional during disease conditions.  Moreover, 
in both models increased activation of phospho-STAT-3 was observed mainly in 
alveolar epithelial cells (AECs) in the airways.  Genetic removal and 
neutralization of IL-6 in both models was associated with decreased phospho-
STAT-3 in AECs and attenuation of fibrosis.  Since mainly hepatocytes and 
leukocytes express the mIL-6Rα, these observations imply that the observed IL-6 
dependent activation in AECs involves IL-6 trans-signaling.  Thus, I hypothesized 
that  IL-6  trans-signaling  through  STAT-3  activation  promotes  EMT in AECs.   
 
118 
 
 
 
 
 
 
 
Figure 5.2 
Elevation levels of sIL-6Rα in ADA-deficient mice and bleomycin model.  
 
(a) Measurements of sIL-6Rα in Ada-/- mice and bleomycin exposed mice. Data 
presented as ng/ml BAL fluid ± SEM, n≥8 (*, p ≤ 0.05 Ada+ vs Ada-/- and wild type 
PBS vs wild type bleomycin). 
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To address this, I directly exposed several airway epithelial  cells  lines  (A549, 
MLE-12, and MLE-15)  to  IL-6 or sIL-6Rα together with IL-6 and examined 
STAT-3 activation and EMT markers.  Results revealed that both IL-6 classical 
and trans-signaling could promote morphological changes in airway epithelial 
cells consistent with EMT (Fig. 5.3).  Furthermore, western blot analysis of cell 
lysates revealed that both IL-6 and sIL-6Rα exposure led to increased STAT-3 
activation; however, sIL-6Rα provided enhanced activation over that seen with 
IL-6 alone (Fig. 5.4).  Examination of EMT markers revealed that both IL-6 and 
sIL-6Rα could directly promote EMT with sIL-6Rα exhibiting amplification of EMT 
relative to IL-6 alone.  EMT was determined by decreased expression of E-cad 
and increased expression of mesenchymal markers such as vimentin and α-SMA 
(Fig. 5.4).  These findings suggest that IL-6 trans-signaling can directly promote 
EMT in AECs. 
 
Examination of the signaling mechanism by which IL-6 regulates the 
induction of EMT in these cell lines revealed that TWIST activation was 
enhanced with exposure of both IL-6 and the sIL-6Ra (Fig 5.4).  TWIST has been 
demonstrated to be a master regulator of EMT (194).  Also, TWIST activation has 
been shown to play a prominent role in EMT in association with cancer 
metastasis (195).  Furthermore, in breast cancer cell line, IL-6 was able to induce 
EMT via increased activation of TWIST (193).  Hence, this indicates that IL-6 
stimulation is associated with activation of TWIST and EMT induction.  In this 
chapter, the results provided demonstrate that exposure of IL-6 and sIL-6Rα to  
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Figure 5.3 
Morphological changes induce by IL-6 trans-signaling in cell culture 
studies 
 
MLE-12, MLE-15 and A549 airway epithelial cells were all used for the 
assessment of EMT. These cells were treated with media as negative control, 
TGF-β as positive control.  Experimental treatment included IL-6 alone, sIL-6Rα 
alone, and IL-6 and sIL-6Rα in combination to test the effect of IL-6 trans-
signaling.  In this figure, MLE-12 cell lines are shown.  Similar findings were 
observed for all cell lines (data not shown). 
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Figure 5.4 
Characterization of IL-6 trans-signaling in cell culture studies.  
 
MLE-12 cells were treated with IL-6 alone, sIL-6Rα alone, and with IL-6 and sIL-
6Rα together. TGF-β was used as the positive control for EMT.  This figure is a 
representative of 10 different experiments where MLE-12 cell lines were exposed 
to the different agents for 72 hours.  Western blot analysis for phospho-STAT-3, 
TWIST, and EMT markers on MLE-12 cells under no treatment or treatment with 
TGF-β, IL-6 alone, sIL-6Rα alone or the IL-6/sIL-6Rα complex. EMT markers 
included E-cadherin (E-cad), vimentin and α-smooth muscle actin (α-SMA).  
GAPDH was used as a loading control. 
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alveolar epithelial cell lines led to EMT induction in conjunction with increased 
STAT-3 and TWIST activation (Fig 5.4).  These results suggest that IL-6 trans-
signaling is involved in regulating fibrosis by enhancing EMT via activation of the 
transcription factors STAT-3 and TWIST. 
 
IL-6 EXPRESSION AND STAT-3 ACTIVATION IN PATIENTS WITH 
PULMONARY FIBROSIS 
 
The findings observed in both models, the Ada-/- mice and the bleomycin 
model, suggested that IL-6 is involved in the regulation of fibrosis.   Also, in vitro 
studies indicated that IL-6 trans-signaling is able to enhance EMT induction.  To 
determine if these findings are relevant to human disease, this signaling pathway 
was examined in tissue sections from patients of severe IPF in comparison with 
mild disease patients.  Tissue sections from surgical biopsies obtained from the 
Lung Tissue Research Consortium were subjected to IL-6 and phospho-STAT-3 
immunostaining.  Patients with preserved lung function (FEV and FVC > 80%) do 
not express IL-6 or phospho-STAT-3 in the alveolar airways (Fig 5.6a, left 
panels).  However, in Stage 4 COPD patients (FEV < 50%), IL-6 was expressed 
in inflammatory cells, mostly alveolar macrophages, whereas phospho-STAT-3 
was detected in alveolar epithelial cells (Fig 5.6a, middle panel).  In Severe IPF 
patients (FVC < 50%), IL-6 was localized in hyperplastic epithelial cells in 
remodeled airways adjacent to fibroblast foci and phospho-STAT-3 nuclear 
localization was observed in hyperplastic alveolar epithelial cells (Fig6a, right 
panels).   Western  blot  analysis  on  lung homogenates from the same patients  
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Figure 5.5 
Characterization of IL-6 expression and STAT-3 activation in human IPF 
patients  
 
Western Blot analysis for IL-6 and phospho-STAT-3 expression on human 
patients with stage 4 COPD and severe IPF.  Tissue sections from surgical 
biopsies were obtained from the Lung Tissue Research Consortium. Patients 
with preserved lung function (FEV and FVC > 80%) were used as normal.  Stage 
4 COPD patients (FEV < 50%) and severe IPF patients (FVC < 50%) were 
subjected to IL-6 and phospho-STAT-3 immunostaining. 
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Figure 5.6 
Characterization of IL-6 trans-signaling in human IPF patients 
 
(a) Immunolocalization of IL-6 and phospho-STAT-3 expression on alveolar 
macrophages (red arrows) and alveolar epithelial cells (blue arrows) in lung 
sections from patients of COPD stage 4 and severe IPF. Images are 
representative of 4 patients from each group. Scale bars: 50 µm. (b) 
Measurements of sIL-6Rα in BAL fluid using ELISA in a COPD patient and from 
two different lobes from the same IPF patient, right middle lobe (RML) and lower 
left lobe (LLL). 
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demonstrated increased expression of IL-6 and phospho-STAT-3 in both Stage 4 
COPD and Severe IPF patients (Fig 5b).  These results confirm the observations 
seen in mouse models and demonstrate that key components of IL6-signaling 
are elevated in patients with COPD and IPF. 
In addition, we demonstrated that the sIL-6Rα is elevated in patients of 
severe IPF.  An ELISA specific for sIL-6Rα was used and revealed a marked 
increase in sIL-6Rα levels in the lavage fluid from a COPD patient and from two 
different lobes from the same IPF patient, right middle lobe (RML) and lower left 
lobe (LLL).  Interestingly, in the IPF patient only the LLL demonstrated elevations 
of the sIL-6Rα.  These results suggest that generation of sIL-6Rα is locally 
produced at the site of injury and that IL-6 trans-signaling is associated with 
active disease. 
 
DISCUSSION 
Our findings demonstrate that increased elevations of IL-6 are associated 
with increased STAT-3 activation in AECs.  Activation of STAT-3 in AECs has 
been previously reported (196-199).  Conditional deletion of STAT-3 in type II 
AECs results in mice being susceptible to pulmonary damage once exposed to 
hyperoxia (196) and adenoviral infection (197).  During endotoxin-mediated lung 
injury STAT-3 regulates surfactant phospholipid synthesis and secretion (198).  
These studies in acute lung injury reveal a role of STAT-3 in type II AECs mainly 
in maintenance of surfactant homeostasis (199).  Another analysis performing a 
genome wide mRNA analysis revealed that specific deletion of STAT-3 in type II 
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AECs resulted in altered gene expression involved in cell growth, apoptosis, and 
lipid metabolism (200).  These studies demonstrate that STAT-3 provides a 
protective effect in respiratory epithelial cells during acute lung injury.  However, 
the role of STAT-3 in the setting of chronic inflammation and remodeling has not 
been addressed.   My findings indicate that genetic removal and neutralization of 
IL-6 results in attenuated fibrosis in association with decreased STAT-3 
activation in type II AECs.  This suggests that the mechanisms by which IL-6 
promotes fibrosis might involve STAT-3 activation in type II AECs.   
One possible mechanism by which type II AECs might be involved in 
fibrosis is through the process known as EMT.  Although the role of IL-6 on type 
II AECs with regards to EMT remains to be investigated, the potential of IL-6 to 
induce EMT in other cell types have been confirmed.   In human breast cancer 
cells, IL-6 is able to induce EMT phenotype by activating STAT-3 and up-
regulating the expression of vimentin, N-cadherin, Snail, and Twist, in 
conjunction with impaired expression of E-cadherin (193).  Other reports 
demonstrate that STAT-3 trans-activates Twist gene expression (201), which is a 
transcription factor involved in the activation of EMT.  In addition, in ovarian 
carcinomas, crosstalk between EGF and IL-6Rα mediates EMT by increasing N-
cadherin and vimentin expression in a STAT-3 dependent manner (202).  Other 
reports have studied the role of IL-6 in mesenchymal cells, human airway smooth 
muscle cells were reported not to express the mIL-6Rα and exposure to IL-6 
trans-signaling resulted in an increased expression of eotaxin and VEGF (203).  
IL-6 trans-signaling on human airway epithelial cells in response to bacteria 
127 
 
pathogens lead to activation of MCP-1 and inhibition of IL-8 in the same cells 
(204).  Hence, bacterial stimulation on airway epithelial cells induces IL-6 
expression and activates IL-6Rα shedding by TACE subsequently promoting 
autocrine–mediated IL-6 trans-signaling events.  Similar results involving 
exposure of azoxymethane to mice leads to colonic epithelial cells inducing sIL-
6Rα biosynthesis and STAT-3 activation, which in turns accelerates colon 
carcinogenesis (205).  Other studies confirm that mice exposed to dextran 
sodium sulfate leads to colon carcinogenesis but through the induction of the IL-
6/sIL-6Rα complex by laminar propia macrophages on colonic epithelial cells 
(206).  This effect was associated with increased gp130 and decreased IL-6Rα 
expression on colonic epithelial cells, suggesting a synchronized upregulation of 
IL-6 trans-signaling and reduction of classical IL-6 signaling.   Accordingly, it has 
been established that classical signaling is associated with anti-inflammatory 
properties while trans-signaling with chronic and pro-inflammatory effects.  
Hence, it is conceivable that IL-6 might play diverse roles on epithelial cells, 
displaying protective effects via classical signaling and perhaps chronic and 
remodeling properties by means of trans-signaling activation.  Our findings 
suggest a fibrotic contribution of IL-6 in type II AECs via the STAT-3 pathway in 
both models analyzed.  Induction of EMT was observed on different alveolar 
epithelial cell lines with exposure to IL-6 in combination with the sIL-6Rα.  The IL-
6/sIL-6Rα complex was able to enhance EMT by increasing expression of 
vimentin and α-SMA in these cells.  Furthermore, induction of EMT by the IL-
6/sIL-6Rα complex was shown to be associated with enhanced activation of the 
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transcription factors STAT-3 and TWIST, which is a master regulator of EMT.  
TWIST is a known transcription factor involved in the regulation of metastasis, a 
multistep process where primary tumors spread to establish secondary tumors in 
distant sites (195).  TWIST is a master regulator of embryonic morphogenesis 
and contributes to tumor metastasis by promoting EMT (195).  It has been shown 
that TWIST is able to induce loss of E-cadherin-mediated cell-cell adhesion, 
promote cell motility, and induce mesenchymal markers (195).  Hence, activation 
of TWIST via STAT-3 establishes a link between IL-6 and EMT.  Thus, this IL-
6/sIL-6Rα complex provides an alternative pathway by which IL-6 could 
potentially mediate the fibrotic development caused by increased adenosine 
concentrations.   
Several studies have reported elevations of IL-6 in patients of 
inflammatory and fibrotic lung diseases such as asthma, COPD, sarcoidosis, 
cystic fibrosis, and IPF (113, 114, 121).  For instance, bronchial epithelial cells 
and mast cells from asthmatics produce IL-6 (117, 207), and alveolar 
macrophages from asthmatics secrete IL-6 upon allergen exposure (115).   In 
addition, BALF and sputum from symptomatic asthmatics have increased IL-6 
levels compared to asymptomatic asthmatics (118).  These findings suggest that 
IL-6 is involved in the pathogenesis of many lung diseases.  To further 
corroborate our findings and the importance of IL-6 signaling from COPD and IPF 
patients, we analyzed the expression of IL-6 and phospho-STAT-3 in lung tissue 
obtained from the Lung Tissue Research Consortium (LTRC).  Patients with 
preserved lung function were used as control group in comparison to stage 4 
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COPD and severe IPF patients.  In COPD patients, increased IL-6 expression 
was observed mainly on macrophages whereas increased STAT-3 activation 
was detected in alveolar epithelial cells.  This suggests a paracrine loop between 
inflammatory cells producing IL-6 and AECs being the cellular targets thereby 
augmenting disease conditions.  In severe IPF patients, both IL-6 and phopho-
STAT-3 expression were localized in hyperplastic epithelial cells.  This suggests 
an autocrine IL-6 signaling where remodeled airway epithelial cells are both 
secreting and being the target of IL-6.  This autocrine feedback loop represents a 
plausible mechanism by which IL-6 signaling exacerbates fibrotic pathologies by 
contributing to the differentiation of hyperplastic epithelial cells and increasing 
fibroblast foci accumulation, which are the site of active disease.  In addition, it 
has been shown that following the engagement of the A2BR on alveolar 
macrophages isolated from COPD and IPF patients produce increased IL-6 
transcript and protein levels (208).  Furthermore, elevations of the sIL-6Rα were 
only detected at the affected lobe from the patient of IPF.  The same patient did 
not demonstrated increased elevations of the sIL-6Rα from the unaffected lobe.  
This clearly indicates that the production of the sIL-6Rα is only generated in the 
setting of chronic injury.  Thus, the sIL-6Rα levels are a clear indication of 
disease severity.  These results substantiate the findings observed in our mouse 
models further demonstrating the relevance and importance of IL-6 signaling in 
human lung diseases.  These studies have important implications for the use of 
adenosine and/or IL-6 blocking reagents in the treatment of pulmonary disorders 
where fibrosis is a detrimental component. 
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CONCLUSION 
Substantial information and studies demonstrate that adenosine 
elevations regulate pathways that promote the pathogenesis of chronic lung 
diseases.  Studies in the Ada-/- mice, an adenosine-mediated pulmonary injury 
model, reveal that adenosine is sufficient to regulate aspects of pulmonary 
phenotypes; however, the mechanism by which adenosine is able to regulate the 
chronic state of these diseases via the mediation of different factors remains 
unknown.  My overall findings suggest that increased elevations of IL-6 are 
associated with increased STAT-3 activation in conjunction with increased 
pulmonary inflammation, alveolar destruction, and fibrosis (Fig 6.1).  In this 
dissertation, experiments in Chapter Three demonstrate that macrophages and 
bronchial epithelial cells are the source of adenosine-driven IL-6 elevation, 
whereas alveolar epithelial cells are target cells of IL-6 via STAT-3 activation.  In 
addition, genetic removal and neutralization of IL-6 in Ada-/- mice is associated 
with diminished airway remodeling, attenuated lung inflammation, and reduced 
fibrosis in conjunction with decreased STAT-3 activation.  Furthermore, 
experiments in Chapter Four utilized the bleomycin model, which is the most 
common model of pulmonary fibrosis to assess the therapeutic potential of anti-
fibrotic agents.  The genetic removal and neutralization of IL-6 in the bleomycin 
model is associated with decreased lung inflammation and attenuated fibrosis in 
conjunction with diminished STAT-3 activation.  Therefore, our findings from 
Chapter Three and Four and published results in the literature suggest an 
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essential role of IL-6 in the pathogenesis of inflammatory and fibrotic lung 
diseases.   
These chapters indicate that targeting IL-6 can provide potential 
therapeutic benefits for chronic inflammatory and fibrotic diseases.  Moreover, 
experiments in Chapter Five focus on determining the mechanism of action by 
which IL-6 induces fibrosis (Fig 6.1).  IL-6 trans-signaling is elevated in Ada-/- 
mice and the bleomycin model.  Also, IL-6 trans-signaling enhances EMT in vitro.  
This enhancement of EMT is characterized by increased expression of vimentin 
and α-SMA in association with increased activation of STAT-3 and TWIST, a 
known master regulator of EMT.  To the best of our knowledge, these 
experiments are the first to show IL-6 trans-signaling has direct fibrotic properties 
on alveolar epithelial cells.  Also in Chapter Five, our findings in our models were 
corroborated in the lungs of IPF patients.  Also, sIL-6Rα levels were elevated in 
BALF from the affected lobe of an IPF patient together with increased IL-6 and 
STAT-3 activation.  Thus, these studies demonstrate that IL-6 contributes to the 
inflammatory and fibrotic processes involved in chronic lung diseases.  Thus, our 
working model is that elevated adenosine engages the A2BR to increase IL-6 
production from macrophages.  In turn, IL-6 activates STAT-3 in target cells, 
mainly alveolar epithelial cells, to contribute to the pathology associated with 
these models via trans-signaling.  Based on this research, treatment with the IL-6 
neutralizing antibodies leads to the functional halting of STAT-3 activation in 
alveolar epithelial cells, which consequently inhibits the transcriptional activation 
of the pathways involved in the development of the chronic pathological 
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symptoms observed in these models.  Thus, IL-6 is involved in the development 
of pathological features associated with adenosine-mediated pulmonary injury 
and bleomycin-induced pulmonary fibrosis.  These observations indicate that IL-6 
signaling represents a potential therapeutic target for chronic lung diseases.   
 
FUTURE DIRECTIONS 
DETERMINATION OF THE SOURCE OF SOLUBLE IL-6 RECEPTOR 
This dissertation demonstrated that IL-6 trans-signaling is functional in the 
setting of pathological conditions in both Ada-/- mice and the bleomycin model.  
Yet, one question remains unanswered, namely what is the source of the sIL-
6rα?  To determine the cells that produce the proteolytic cleavage sIL-6R (PC-
sIL-6R), an experiment will be performed where isolated macrophages from both 
models will be analyzed using immunostaining for the expression of the mIL-6Rα.  
After confirming that these macrophages express the mIL-6Rα, they will be 
incubated with the known protease ADAM17.  This incubation is expected to 
generate the PC-sIL-6R.  In addition, an ADAM17 inhibitor will be introduced to 
test if the PC-sIL-6R production is prevented.  Measurements of ADAM17 with an 
ELISA assay in the plasma and BALF will further demonstrate the local 
production responsible for the increased sIL-6R levels.  
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Figure 6.1 
Working Model 
 
After tissue injury, elevated adenosine levels engage the A2BR on activated 
macrophages (M2) leading to increased IL-6 production and IL-6Rα shedding.   
IL-6 trans-signaling involves the binding of the IL-6/sIL-6Rα complex to gp130 
receptors on type II alveolar epithelial cells (AECs) resulting in the 
phosphorylation and nuclear translocation of STAT-3.  Activation of STAT-3 on 
these cells acts as a transcription factor in target genes that enhance the process 
of epithelial-to-mesenchymal transition (EMT), which is known to contribute to 
fibrosis via the accumulation of myofibroblasts and collagen production. 
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Our results demonstrated that measurements of the sIL-6Rα in the BALF 
and plasma from both models indicated that the sIL-6Rα is produced locally 
rather than systemically.  This is inferred since only BALF and not plasma display 
increased sIL-6Rα levels.  However, in this study no confirmation was made as 
to which sIL-6Rα isoform was increased during disease conditions of both 
models.  Thus, differentiation of the two sIL-6Rα isoforms needs to be done in 
order indicate the predominance of the alternative spliced sIL-6Rα (AS-sIL-6Rα) 
or the proteolytic cleavage sIL-6Rα (PC-sIL-6Rα).  To confirm the generation 
mechanism of the sIL-6Rα, an ELISA against the recognition sequence of the 
AS-sIL-6Rα will be used from both plasma and BALF.  Detecting the levels of the 
AS-sIL-6Rα from both the plasma and BALF will demonstrate if the increased 
sIL-6Rα levels are produced locally by proteolytic cleavage or systemically by the 
alternative splice mechanism. 
In addition, our results from BALF obtained from human patients of IPF 
demonstrated that sIL-6Rα levels are elevated in the affected lobes of the 
individual whereas unaffected lobes display decreased levels of this receptor.  
This suggests that the sIL-6Rα is generated only at the site of injury and 
increased levels of this receptor correlate with disease severity.  However, our 
results are derived only from one patient due to the difficulty in obtaining human 
samples for basic research.  Thus, future directions involved to further increase 
the number of human patients analyzed to corroborate these findings. 
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CHARACTERIZATION OF THE EFFECT OF STAT-3 INHIBITION ON IL-6-
INDUCED FIBROSIS 
  
Observations in this dissertation demonstrated that IL-6-dependent 
increased phospho-STAT-3 activation is associated with pulmonary pathology.  
However, at this stage it is difficult to determine cause and effect between 
phospho-STAT-3 and pulmonary pathology or fibrosis.  To assess the 
contribution of IL-6 via the STAT-3 pathway to the fibrotic response, type II AECs 
in the presence of IL-6 and the sIL-6Rα will be treated with an STAT-3 siRNA.  
As a control, a scramble siRNA will be used to treat these cells. Treatment of IL-
6-activated type II AECs with the STAT-3 siRNA will determine which of the IL-6 
activities related to fibrosis are activated by the STAT-3 pathway. If IL-6 induces 
EMT on type II AECs via the STAT-3 pathway, then treatment with the STAT-3 
siRNA will be able to preserve the ATII phenotype and prevent the excessive 
ECM deposition common to fibrogenesis. 
Treatment with the selective STAT-3 inhibitor CPA-7 can be used as a 
confirmatory assay to determine the effect of IL-6 via the STAT-3 or as an 
alternative approach in case the siRNA targeted approach does not completely 
silence the STAT-3 gene. An additional alternative approach will consists of 
obtaining primary type II AECs from conditional STAT-3 knockout mice. Treating 
these type II AECs, which do not express STAT-3, will not develop the EMT 
effects presumably induced by IL-6. In case that the MAPK or PI3K pathway is 
involved for fibrotic activities, the same approach will be used, namely the siRNA 
target approach and pharmacological inhibitors for ERK and Akt. 
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Assessment of the pathway by which IL-6 contributes to features of 
pulmonary fibrosis is limited to the STAT-3 pathway. Although IL-6 activation is 
thought to be mainly STAT-3 mediated, other downstream signaling pathways 
are activated besides the STAT-3 such as the Ras/Raf/Mitogen-Activated Protein 
Kinases (MAPKs)/ERK and the phosphatidylinositol 3-kinase (PI3K)/Akt. These 
pathways are activated by IL-6 and elicit a variety of responses such as myeloma 
cell growth, survival, and drug resistance via the MAP Kinase pathway (209) and 
protection from TGF-β-induced apoptosis on hepatoma cells via the PI3K 
pathway (210). Therefore, an alternative approach to assess the mechanism 
involved in IL-6-induced fibrosis will include measuring the activity of the 
MAPK/ERK and the PI3K/Akt pathways. Western blot analysis measuring ERK 
and Akt phosphorylated proteins will determine the activity of these pathways 
when type II AECs are treated with IL-6 and sIL-6R together. 
 
DETERMINATION OF EPITHELIAL-TO-MESENCHYMAL TRANSITION IN THE 
ADA-DEFICIENT MICE AND THE BLEOMYCIN MODEL. 
 
Although on the previous chapter it was demonstrated in vitro that IL-6 
trans-signaling is able to enhance EMT in alveolar epithelial cell lines, no direct 
evidence was provided that this process is occurring in vivo.  To move from in 
vitro experiments to an in vivo setting, lung sections from Ada-/- mice and 
bleomycin-exposed mice will be triple stained for E-cadherin, phospho-STAT-3, 
and α-SMA. This triple staining will allow identifying type II AECs that are 
transitioning in losing their epithelial-like phenotype (E-cadherin) and becoming 
mesenchymal in nature (α-SMA).  The phospho-STAT-3 staining will identify the 
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cells that are undergoing EMT due to STAT-3 activation. According to our results, 
Ada-/- mice and bleomycin-exposed mice subjected to genetic removal or 
neutralization of should demonstrate reduced expression of this transitioning 
phase.  Thus, future studies will determine the in vivo role of IL-6 in inducing 
EMT on type II AECs, which is the remodeling effect seen in pulmonary fibrosis 
(158, 166). 
 
IL-6 AS A THERAPEUTIC TARGET FOR CHRONIC LUNG DISEASE 
The results obtained from this dissertation indicate that targeting IL-6 
could be beneficial in patients with chronic lung disease.  In particular, it was 
demonstrated that pulmonary fibrosis is attenuated by blocking IL-6 in mice.  
Tocilizumab or Actemra is a humanized monoclonal antibody (mAb) targeting the 
IL-6 receptor (91), which inhibits both IL-6 classical and trans-signaling.  The 
development of this humanized anti-IL-6 receptor mAb was pioneered for the 
treatment of the rare Castleman’s disease and later was approved to treat 
rheumatoid arthritis (RA) (211).  Significant improvement was observed in RA 
patients treated with Actemra compared to standard treatments alone.  However, 
IL-6 blockers have not been considered for the treatment of chronic lung 
diseases.  Considerations in using a humanized mAb against IL-6 must include 
the potential adverse effects of blocking such a pleiotropic cytokine.  The main 
side-effect in blocking IL-6 could be the inability of the immune system to fight 
infections caused by bacteria, fungi, or viruses.  It has been reported that RA 
patients while taking Actemra have died from these infections, such as 
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tuberculosis and Epstein-Barr virus (211).  In addition, other side-effects include 
gastrointestinal perforation, neutropenia, thrombocytopenia, increased liver 
enzymes, and elevated lipid parameters (212).  Actemra is a genetically-
engineered mAb that is humanized from a mouse antihuman IL-6 receptor using 
the complementarity determining regions (CDRs), which are the most variable 
part of the antibody and determine its affinity and specificity for specific antigens.  
The humanized anti-human IL-6 receptor antibody has resulted in reduced 
antigenicity in humans.  Thus, the advantage of using humanized Actemra is 
prolongation of its half-life and rarely causes production of neutralizing antibodies 
against the drug.  Inhibition of IL-6 may also aid this feature since IL-6 induces 
antibody production (211).       
IL-6 is a major player in driving the immune system with the potential to 
have pro- or anti-inflammatory properties.  IL-6 remains at low levels in healthy 
individuals but increases dramatically during an immune response targeting 
different immune cells, such as monocytes, macrophages, dendritic dells, B cells 
and T cells.  In response to injury, infection, or other factors, IL-6 induces an 
acute phase reaction marked by an increase in acute-phase proteins such as C-
reactive protein and fibrinogen.  In addition, IL-6 not only favors the shift to a Th2 
over Th1 response; but in combination with TGF-β, IL-6 is able to inhibit Treg 
cells and induce Th17 differentiation marked by increased IL-17 production.  This 
Th17 subset of T cells is involved in autoimmune diseases.  To add to this 
complexity, IL-6 is able to activate cells that lack the mIL-6Rα by forming the IL-
6/sIL-6Rα complex and binding to gp130, a process known as trans-signaling.  
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Hence, this complexity provides three different ways to inhibit IL-6 signaling by 
blocking the cytokine, the receptor, or the IL-6/sIL-6-Rα complex.  Blocking IL-6 
signaling with humanized mAb against the receptor is associated with a degree 
of abnormalities.  Targeting IL-6 and not the receptor presumably is associated 
with reduced side effects, especially in the liver since hepatocytes highly express 
the mIL-6Rα.  This makes IL-6 a decidedly more attractive therapeutic target.  
The third option is to block just IL-6 trans-signaling.  This can be done by 
trapping the IL-6/sIL-6Rα complex with the soluble gp130 fusion protein thereby 
preventing the activation of target cells.  This resembles more a natural 
mechanism by allowing classical IL-6 signaling to be functional and most 
probably with an improved side-effect profile.   The most common side-effect in 
IL-6 and IL-6 receptor blocking antibodies is the susceptibility to opportunistic 
infections since it weakens the body’s immune defense.  However, blocking IL-6 
trans-signaling allows classical signaling to be activated as needed.  
Nevertheless, there is a need for clinical trials to determine which of these 
inhibitors compared to one another would be better for a particular disease.    
Regarding inhibition of IL-6 signaling in patients with Chronic Lung 
Disease, therapeutic trials need to be performed to determine the efficacy and 
safety of these different blockers of IL-6.  The different approaches to block IL-6 
signaling are to inhibit IL-6 production (A2BR antagonism), direct neutralization of 
IL-6, blockage to the IL-6 receptor, and abduction of the IL-6/sIL-6R-α.  Another 
possibility is to inhibit the intracytoplasmic gp130 signal, thereby inhibiting STAT-
3 activation.  Concerning the role of IL-6 in pulmonary fibrosis, treatment of IPF 
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patients with the different options of blocking IL-6 signaling would determine 
which approach is more beneficial by monitoring the outcome and assessing the 
side-effects.   Hence, long-term observational studies using these approaches in 
patients with IPF are needed to determine the efficacy of blocking IL-6 in chronic 
lung disease. 
 
SUMMARY 
This dissertation focuses on the confirmation of the contribution of IL-6 to 
features of inflammatory and fibrotic lung diseases in both the Ada-/- mice and 
bleomycin-exposed mice in order to provide a better understanding of the 
development of these diseases. Collectively, the neutralization of IL-6 and the 
genetic removal of IL-6 in both models provided a comprehensive analysis 
regarding the contribution of IL-6 to disease progression in these models.  
Hence, the IL-6 signaling mechanism represents a potential therapeutic 
application for these deadly disorders. 
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